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CHAPTER I 
 
INTRODUCTION 
 
Overview 
 Cellular signals propagated by the small protein modifier Ubiquitin (Ub) 
are indispensible for maintaining cellular homeostasis. Ub signaling plays major roles in 
protein localization, DNA repair, transcription activation, chaperone response, and cell 
stress most frequently resulting in targeting substrates for degradation by the 26S 
proteasome (1-4). Flaws in ubiquitination can be devastating to cellular regulation and 
lead to physiological defects like the neurological disorder Parkinson‟s Disease, as well 
as a variety of cancers such as breast, ovarian, and specific classes of lymphoma (5).   
The role of ubiquitin in targeted protein degradation is now well established. 
Ubiquitin mediated proteolysis plays a significant role in a range of important cellular 
functions (6). Endoplasmic Reticulum Associated Degradation (ERAD), which is 
essential for degradation of misfolded or unfolded protein species, is arguably the most 
well studied example. Ub-meidated proteolysis is also essential to progression through 
the cell cycle, in particular at the conclusion of mitosis where poly-ubiquitination and 
subsequent degradation of cyclins signals transition from mitosis to G1 (reviewed in (7)). 
 The levels of the well-known tumor suppressor p53 are kept low by ubiquitin-dependent 
proteolysis its degradation must be inhibited to initiate p53 signaling reviewed in (8). 
Recent investigations of the Ub system also reveal critical roles in non-proteolytic 
signaling pathways. This includes activation of histones, where monoubiquitination 
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signals for the chromatin unwinding that allows transcription associated factors access to 
bind DNA and intiation of transcription (9). Another important role for non-proteolytic 
Ub signaling is internalization and endocytosis of various membrane bound proteins (1). 
During DNA double strand break repair, ubiquitination associated proteins such as 
BRCA1, RNF8, and Ubc13 are recruited to sites of chromatin damage where it has been 
suggested that Ub
K63
 chains help escalate the DNA damage response (10). 
  Unlike small molecule post-translational modifications, ubiquitination requires 
multiple enzymatic reactions. Precise coordination between three classes of enzymes (E1, 
E2, and E3) governs the fate of the target substrate. More specifically, the exact type of 
ubiquitination that occurs is dependent upon which particular E2 and E3 enzymes are 
involved. It is currently believed that the specific combination of E2-E3 pairs determines 
whether a substrate is mono- or poly-ubiquitinated, and if the latter, what topology of Ub 
chain is generated (11-13). While previous studies have characterized the steps of the 
ubiquitination cascade, current research suggests that there is still a wide gap in 
knowledge in understanding the molecular mechanisms that govern ubiquitination.  
 The research described in this dissertation analyzes the mammalian E3 ubiquitin 
ligase, E4B, and assesses its influence on the E2~Ub conjugate. E4B is a unique 
monomeric U-box E3 ligase that provides a powerful tool for the study of the mechanism 
of ubiquitination. The results described here provide insight into the structure, E2 binding 
characteristics, and the activation of the E2~Ub conjugate by an E3 ligase. This work 
provides a foundation for future studies directed to further understand the basis for 
ubiquitin-substrate specificity. 
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Ubiquitination and cellular signaling 
Ubiquitin is a 76 amino acid β-grasp fold protein that was originally described as 
a lymphocyte differentiation factor (14) (Figure 1.1). Ubiquitin was so named because of 
its universal presence in most cellular species in addition to its extremely high degree of 
conservation. Groundbreaking work by Ciecanhover, Hershko, and Rose demonstrated 
Ub‟s function as a unique ATP-dependent proteolysis factor 
 
 
crucial for protein degradation in the absence of lysosomes (16, 17). Ubiquitin was 
shown to uniquely modify other proteins through covalent linkage and generate high 
molecular weight species, an observation that was necessary for the eventual degradation 
of the substrate (18). Further work established the role of the 26S proteasome in this 
system. (19).   
Figure 1.1. Structure of Ubiquitin. A) Surface diagram B) Cartoon representation 
showcasing lysine side chains. Produced from PDB ID 1UBQ (15). 
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Ubiquitin contains several unique structural features that enable it to interact with 
a vast number of proteins in the cell, as well as with itself. For example, the majority of 
protein-protein interactions mediated by ubiquitin are done so through a critical 
hydrophobic patch composed of residues Leu8, Ile44, and Val70. The C-terminal tail of 
ubiquitin is exposed, and allows for the covalent attachment of Ub to a variety of 
substrates via linkage with the ε-amino side chain of a lysine residue. Ubiquitin itself 
contains seven lysine residues (6, 11, 27, 29, 33, 48, and 63) which form the basis for 
poly-ubiquitin chain synthesis. Together, ubiquitin can mediate a diverse array of protein-
protein interactions as well as propagate a variety of cellular signals through 
polyubiquitin chain formation.  
 
Ubiquitin Binding Domains   
When a substrate undergoes a PTM, the chemical and physical properties of that 
protein are altered. Ubiquitination of a target protein not only changes the structural 
landscape of that target, but it may also act as a new binding domain for other molecules. 
Furthermore, ubiquitin can also block other PTMs as well as protein-protein interactions 
between the substrate and other targets. Throughout the human proteome, approximately 
20 types of ubiquitin-binding-domains (UBDs) exist (20) (Figure 1.2). 
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Figure 1.2. Ubiquitin Binding Domains A) Surface representation of Ubiquitin with 
essential hydrophobic patch highlighted in yellow. Ubiquitin bound to B) UBA domain 
of Ubiquilin (wheat, PDB ID: 2JY6 (21)); C) UBA domain of Cbl-b (violet, 2OOB (22)); 
D) UBA domain of Edd (teal, 2QHO (23)); E) CUE domain of Cue2 (light-green, 1OTR 
(24)); F) Miz domain of S5a (beige, 1YX5 (25)). G) Model of UBA domain of Rad23 
bound to di-Ub
K48
 (purple,  1ZO6). F) NZF domain of TAB2 bound to di-Ub
K63
 (orange, 
3A9J (26)).  
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Proteins containing these domains recognize and interact with Ub-modified substrates, 
depending on the type of Ub modification that has occured. Most often, UBDs utilize α-
helical motifs to bind a critically conserved Ile44 residue exposed on Ub (20). For 
example, Ubiquitin-interaction motifs (UIM) and motifs interacting with Ubiquitin (MIU) 
use single α-helices for Ub binding whereas UBDs such as Ubiquitin-associated domains 
(UBA) and Coupling of Ubiquitin conjugation to Endoplasmic Reticulum Degradation 
domains (CUE) use split α-helices. (20). 
Not all UBDs utilize α-helical structures to interact with Ub. Deubiquitinases 
(DUBs) are necessary to both reverse ubiquitination events as well as recycle Ub species 
at the cap of the proteasome. DUBs employ β-sheets to interact with the strictly 
conserved I44 of Ub (27). Moreover, a select number of E2 ligases also use β-sheets to 
bind Ub in a non-covalent manner, which is necessary for processive poly-ubiquitin chain 
elongation (28). 
 
Ubiquitin Chain Topology 
Perhaps the most unique structural quality of Ub is its ability to form 
polyubiquitin chains, i.e., after initial monoubiquitination of a target protein, the 
ubiquitination process may repeat. Ub can attach covalently to another Ub molecule 
through any one of its 7 lysine residues (K6, K11, K27, K29, K33, K48, and K63) or, to a 
lesser extent, its N-terminal methionine (29). Because the different lysine residues are 
located in different structural areas of Ub, radically different topologies can be formed 
allowing for different UBDs to bind to different chain linkages (Figure 1.3).   
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Figure 1.3. Ubiquitin chain topologies. Hydrophobic Leu8 – Ile44 – Val70 surface 
highlighted in yellow. A) Ubiquitin chain topologies and their known cellular functions 
and incidence. B) di-Ub
K6
 (PDB ID: 2XK5); C) di-Ub
K11
 (3NOB (30)); D) di-Ub
K48
 
(2BGF (31)); E) di-Ub
K63
 (2W9N (29)); F) tetra-Ub
K48
 (2O6V (32)); G) tetra-Ub
K63
 
(3HM3 (33)). Structural information not available for chains of linkages. K27, K29, K33, 
or forked linkages.   
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Formation of a poly-ubiquitin chain on a particular lysine residue has crucial 
implications for the resulting cellular signal. For instance, protein degradation by the 26S 
proteasome is the dénouement of K48 (Ub
K48
) linkages, and is possibly the most widely 
studied aspect of polyubiquitination. When formed, Ub
K48
 chains adopt a distinct packed 
globular conformation, burying the conserved Leu8/Ile44/Val70 hydrophobic patch. 
Burying this patch inhibits the majority of UBDs from interaction with Ub. Therefore, 
this topology is only recognized by UBDs that bind to the specific motifs created between 
the modified K48 and G76 residues of the chain (27).  
It has also been established that several Ub
K48
 binding proteins contain domains 
that mimic the β-grasp Ub-fold. These motifs, termed Ubiquitin Like Motifs (UBLs) bind 
to the protein subunit Npn10 located in the 19S cap of the proteasome (34). The ability of 
Rad23, Dsk2, and Ddi1 to concomitantly bind both Ub
K48
 motifs and proteasome 
subunits defines their central roles in protein degradation.  
 Ub
K63
 chains, on the other hand, adopt linear structures, exposing the majority of 
the Ub surface (27). Most notably, the Leu8/Ile44/Val70 hydrophobic patch is exposed 
allowing a plethora of UBD-containing proteins to recognize and bind Ub, propagating 
diverse cellular signals.  Ub
K63
 chains play critical roles in activation of DNA repair 
checkpoints, most notably through tightly regulated modification of PCNA (35).   
Despite only limited structural knowledge of polyubiquitin chain topologies, 
functional studies have recently demonstrated that Ub
K11
 chains also signal substrates for 
proteasomal degradation (36). Based on these cumulative studies, it is fascinating to note 
that the incidence of Ub
K11
 chains occurring in the cell is approximately 28.0±1.4% 
compared to the 29.1±1.9% and 16.3±0.2% of Ub
K48
 and Ub
K63
, respectively. This 
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suggests a much wider role for Ub
K11
 chains in cellular signaling than previously thought. 
Ub
K11
 is known to modify many substrates, and is a crucial Ub chain topology associated 
with ERAD. At this time, complete structural  
information of Ub
K11
 chains is unknown, and it remains unclear whether unique 
proteasome shuttling factors exist for this Ub chain topology.  
While in vitro studies in yeast have shown that all seven lysine residues of Ub can 
form an anchor for chains, specific cellular functions of all chain types have yet to be 
elucidated (36). Ub
K6
 chains have been shown to play an important role in BRCA1 
mediated DNA damage response, but like Ub
K11
 chains, only limited structural 
information is currently available (37). More perplexing, substrates of Ub
K6
 in this 
process have yet to be identified, so it remains to be determined if BRCA1 (an E3 
ubiquitin ligase) generates this chain topology or if other E3 ligases are necessary for the 
construction of this particular chain.  
It has become increasingly evident that polyUb chains can form from the N-
terminal methionine of Ub in addition to lysine residues as evidenced by the NEMO 
activation of NF-κB (38). In this pathway, the LUBAC E3 ligase complex will first 
ubiquitinate NEMO on specific lysine residues, and then form polyubiquitin chains using 
the N-terminal methionine residue of these ubiquitins. There is also evidence for forked 
Ub chains. These have been observed on multiple lysine residues on a substrate, but the 
cellular implications of this topology have not been determined except to note they do not 
signal for degradation by the proteasome (39). In summary, despite knowing the diverse 
effects of polyubiquitin signaling, the factors governing the elongation of Ub chains have 
yet to be elucidated.  
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The Ubiquitination Cascade 
Ubiquitin modifies proteins through covalent attachment of its C-terminal glycine 
residue to the ε-amino group of an acceptor lysine on the target protein. In order for Ub 
modification to occur, the action of three enzymes must be precisely orchestrated to 
mediate the three steps of the overall reaction (40) (Figure 1.4). First, the E1 activating 
enzyme adenylates the C-terminal glycine of Ub in an ATP dependent manner. This step 
forms a thiolester bond between the catalytic cysteine residue of E1 and the C-terminal 
glycine of Ub. Second, the E1 hands Ub off to an E2 conjugating enzyme, which also 
binds Ub by a thiolester bond between a cysteine in the E2 and the C-terminal glycine in 
Ub. Finally, an E3 ligating enzyme recruits both the target substrate and the E2~Ub 
conjugate. Remarkably, the E2~Ub conjugate is activated by binding the E3 ligating 
enzyme which promotes Ub transfer to a lysine residue of the substrate. Chain building 
involves subsequent steps of E2~Ub activation and transfer to lysines on the Ub 
substrate. In some instances, an additional enzyme, termed an E4 ligase, may be 
necessary to build ubiquitin chains. While it has been shown that such enzymes catalyze 
elongation of Ub chains, it has not been established if the E4 has distinct enzymatic 
properties or if its function is merely a special case of E3 ligase activity.     
Overall, the Ub cascade is a cumulative process that facilitates the recognition of, 
and enzymatic activity on, a large number of substrates. Notably, the number of enzymes 
able to catalyze the successive steps increases. For mammalian ubiquitination, only 2 
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genes encode E1 activating enzymes, more than 30 encode E2 conjugating enzymes, and 
an ever expanding number of genes (currently above 600) code for E3 ligating enzymes 
(5). Along with the fact that E3 ligases can often bind multiple substrates, this hierarchy 
is critical to the complex and diverse nature of substrate modification through 
ubiquitination.  
The E1 activating enzyme: E1 enzymes are large proteins comprised of three 
domains: an adenylation domain, catalytic cysteine domain (CCD), and an E2-interacting 
domain (41) (Figure 1.5). Two ThiF homology motifs form the adenylation domain, 
which bind both ATP•Mg2+ and Ub. The conserved cysteine located in the CCD forms 
the thiolester bond with Ub post-activation. A C-terminal Ubiqutiin fold domain (UFD, 
not to be confused with the Ubiquitin Fusion Degradation family of proteins) recruits the 
E2 conjugating enzymes. Uba1 is the universal E1 enzyme in mammalian cells, which is 
reflected in the fact that the UFD of Uba1 recognizes nearly all E2 enzymes. In contrast 
to Uba1, Uba6 appears to only interact with the E2 enzyme, Use1 (44).   
The E2 conjugating enzyme: There are currently 4 classes of E2 conjugating 
enzymes, though all share a common conserved central domain of approximately 150 
residues consisting of an anti-parallel β-sheet flanked by pairs of α-helices (45) (Figure 
1.6). Class I E2 enzymes only contain the core domain. Class II and III enzymes contain 
additional residues N- or C- terminal to the core domain, respectively. Class IV enzymes 
are rare, and contain additional residues both N- and C-terminal to the core domain.  
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E2 enzymes contain a catalytic cysteine residue that is responsible for forming the 
thiolester bond with the C-terminal glycine of Ub. The most widely studied E2 enzyme, 
UbcH5 defines this group and is a class I E2 enzyme that has 4 mammalian isoforms, 
differing only minimally in amino acid sequence. UbcH5 has been described as a 
promiscuous enzyme because it interacts with the vast majority of E3 ligases and can 
both mono- and poly-ubiquitinate substrates without additional E2 enzymes (46). UbcH5 
is also unique because its anti-parallel β-sheet can bind Ub in a non-covalent manner, and 
this characteristic is essential for the processivity of the enzyme in poly-ubiquitination 
(28). Despite evidence of UbcH5‟s interactions with a broad spectrum of E3 ligases, the 
mechanisms underlying UbcH5 function with regards to substrate modification 
Figure 1.5. E1 activating enzyme. A) Saccharomyces cerevisiae Uba1 crystal structure in 
the absence of ubiquitin bound to the catalytic core. B) Same as (A) but bound to 
ubiquitin. Models generated from PDB ID 3CMM (41). 
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specificity (i.e., monoubiquitination versus lysine-specific polyubiquitination) remain 
unknown.   
  In contrast to UbcH5, Ubc13 appears to have a single function: building Ub
K63
 
chain linkages. Like UbcH5, Ubc13 has been shown to interact with a significant number 
of E3 ligases, but its functions lie solely in non-proteolytic Ub pathways (47). This is 
mediated through a Ubc enzyme variant (Uev), Uev1a (yeast homologe Mms2), that 
interacts with Ubc13 in the cell (48). Formation of the Ubc13/Uev1a heterocomplex is 
necessary for Ubc13 to function in ubiquitination. Unlike Ubc enzymes, Uev1a does not 
contain a catalytic cysteine residue, and thus does not form thiolester bonds with Ub. 
However, like UbcH5, Uev1a binds Ub non-coavalently through its antiparallel β-sheet. 
Therefore, two molecules of Ub are bound in the Ubc13/Uev1a heterocomplex, and 
analogous to UbcH5, both binding sites are crucial for chain building processivity. 
Structural studies of Ubc13/Mms2 show that the orientation of Mms2 with respect to 
Ubc13 during substrate ubiquitination only allows Ub
K63
 construction (49). Specifically, 
Ile44 of ubiquitin interacts with Ile57 of Mms2, and this association is necessary for 
Ub
K63
 chain synthesis. Mutations of these residues to alanine completely abrogate chain 
synthesis of any type.  
 Cdc34 is a class II E2 enzyme that functions with Cul1-containing SCF type E3 
Ubiquitin ligases. This particular enzyme contains a highly acidic C-terminal extension 
that is necessary to propagate a processive Ub
K48
 chain (50). Recently, it has been shown 
that this tail binds to a highly conserved basic cleft of the Cullin subunit within the SCF 
ligase (51). Remarkably, this interaction occurs with a dissociation constant in the 
nanomolar range, but at the same time somehow allows the  
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Figure 1.6. E2 conjugating enzymes. A) UbcH5 (green) bound covalently bound to 
ubiquitin (blue). Insert is close-up of the binding site, detailing interactions between 
UbcH5 active site Cys85 and Ub C-terminal Gly76. Also of interest is the position of 
UbcH5 Asn77 with respect to the bond. (3A33 (42)). B) UbcH5 non-covalently bound to 
ubiquitin. Active site Cys85 from UbcH5 highlighted in red to show distance between 
non-covalent site and active site (2FUH (28)). C) Ubc13(green)/Mms2(grey) heterodimer 
covalently bound to ubiquitin (blue). Active site Cys87 from Ubc13 highlighted in red 
(2GMI (49)).  
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complex to be extremely dynamic. To date, Cdc34 is the only observed in vivo partner of 
the Cul1-SCF Ub ligase, and it has been shown to play a major role in ubiquitination of 
β-catenin, a critical component of the Wnt-signaling pathway that controls 
embryogenesis.    
The E3 ligating enzyme: Like E2 conjugating enzymes, there are multiple classes 
of E3 ligases. These include the U-box, RING, and HECT-type ligases, all named after 
the domain in the ligase that interacts with the E2 enzyme. In addition, E3 ligases can be 
simple (e.g. one protein chain recruits and interacts with both the E2 and the substrate) or 
complex (e.g. multiple proteins are required to facilitate the ligase function) (Figure 1.7). 
E3 ligases can facilitate their function either through one protein chain or as part of a 
protein complex. Some E3 ligases contain a substrate recruitment domain as well as a 
respective E2 binding domain and are completely functional as a single entity. However, 
in some cases, additional proteins are necessary to form a complex where one subunit 
will recruit the substrate and another will bind the E2. The primary example of complex 
E3s is the SCF family, which requires at least 4 different protein subunits for ligase 
function (52).  
HECT domain containing E3 ligases only account for approximately 28 proteins 
out of the hundreds of mammalian E3 ligases. HECT (Homologous to E6 Carboxy-
Terminus) domains were first identified in human papilloma virus (HPV) E6-Associate 
Protein (40). The HECT domain comprises approximately 350 conserved residues 
located in the C-termius of the host protein. Usually, substrate recruitment domains are 
located in the N-terminus of the protein. HECT domains are unique in that the Ub 
molecule is directly transferred from the E2~Ub conjugate, before  
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Figure 1.7. E3 ligating enzymes. A) CHIP asymmetric dimer with insert showing 
dimerization interface mediated by hydrophobic residues in the U-box domain. (2C2L 
(53)) B) Prp19 dimer with residues of the dimerization interface highlighted. (2BAY 
(54)) C) Heterodimer of the RING E3 ligases Mdm2 (blue) and MdmX (green). (2VJF 
(55)) D) Heterodimer of the RING E3 ligases BRCA1 (blue) and BARD1 (green) (1JM7 
(56)). E) Heterodimer of the RING E3 ligases Ring1 (blue) and Bmi1 (green) (2CKL 
(57)). F) Complex SCF E3 ligase (1LDK (58)). 
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subsequent transfer to the substrate (59). Domain comparison of the various HECT 
proteins classifies them into 3 sub-families: Nedd4, HERC, and others. Despite their 
small number and unique mechanism, HECT members do not appear to exhibit 
specialized biological functions. They are involved in regulating a variety of both 
proteolytic and non-proteolytic signaling pathways (reviewed in (59)). 
The majority of E3 ligases fall into the Really Interesting New Gene (RING) 
domain containing family. E3 ligases of this family act as scaffolding proteins, recruiting 
both the target substrate and the E2~Ub conjugate. RING E3 ligases catalyze the transfer 
of Ub from the E2 to the substrate in part by co-localization of the E2~Ub conjugate and 
substrate. However, the E3 ligase also is required for activation of the E2~Ub conjugate 
by an as yet unknown mechanism. RING domains comprise approximately 70 residues 
and are characterized by conserved zinc-chelating sites that are necessary for domain 
stabilization (reviewed in (52)).  
The U-box domain is structurally similar to the RING domain, but does not 
contain Zn
2+
 binding sites. Instead, networks of hydrogen bonds and salt bridges provide 
structural stabilization to the 70 residues that make up the domain (60). The U-box family 
of E3 ligases is the smallest class of ligases with only 7 mammalian proteins identified to 
date.  However, despite this low number, U-box containing E3 ligases have been shown 
to play diverse roles in RNA splicing, chaperone response, and ERAD (61).  
Oligomerization is a critical feature for a number of different U-box and RING E3 
ligases. For example, Prp19p is a U-box E3 ligase associated with the 19 complex of the 
spliceosome, necessary to both stabilize and activate the spliceosome machinery. 
Electron Microscopy (EM) studies revealed that Prp19p forms a tetramer (anti-parallel 
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dimer of dimers), which is required for Prp19p function (62). The central coiled-coil 
domain of Prp19 mediates anti-parallel oligomerization. The short linker between the 
coiled-coil domain and the U-box domain, combined with the close spatial proximity of 
the two U-boxes in the parallel dimer, promotes dimerization of the U-box domain. The 
U-box domain of the co-chaperone CHIP also oligomerizes forming a dimer through its 
coiled-coil domain (53). Remarkably, an x-ray crystal structure of CHIP revealed a 
unique asymmetric structure. This observation is consistent with “half-of-sites binding” 
stoichiometry (only one E2~Ub conjugate binds per CHIP dimer) (63).  
Some RING domains directly mediate dimerization. For example, the RING 
ligase Rad18 forms a homodimer in solution (64). However, the most interesting aspect 
of RING protein oligomerization is the ability to form heterocomplexes. Several E3 
ligases hetero-oligomerize via their RING domains with other members of the RING 
family. This is evident with BRCA1/BARD1, Ring1b/Bmi1, and Mdm2/MdmX (65). In 
each of these examples, however, only one of the RING domains is functional. As for 
CHIP, the purpose of “half-of-sites binding” remains unknown. 
Because E3 ligases recruit and bind the target substrate, it was once thought that 
they were the enzymes responsible for conferring the Ub linkage specificity on the 
substrate. However, recent research shows that the E2 enzyme has a critical role in 
determining the type of ubiquitin chain formed. For example, only specific pairs of E2-
E3 enzymes are able to efficiently elongate ubiquitin chains on specific substrates (11, 
12). 
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The Ufd2/E4B U-box containing E3 ligase 
 “E4” enzyme activity 
 Ufd2 was first isolated in a screen by Varshavsky and colleagues to identify 
proteins associated with the N-end degradation pathway (4). Another protein identified in 
that screen, Ufd4, was shown to be a HECT E3 ligase that ubiquitinated a test substrate 
with low efficiency. These workers also showed that Ufd2 appears to add Ub moieties to 
the previously ubiquitinated substrate. These observations were later confirmed by in 
vitro ubiquitination assays in which reconstituted Ufd2 and Ufd4 were incubated together 
with E1, Ubc4 (yeast homologue of UbcH5), and ATP (66). It was found that while Ufd4 
functioned as an E3 ligase, it did not efficiently ubiquitinate a Ub-Gal fusion substrate. 
Rather, Ufd2 was necessary to form the extended polyubiquitin chains required for 
proteasomal targeting. This work lead to the classification of Ufd2 as an “E4” ligating 
enzyme: one that efficiently catalyzes the elongation of pre-existing polyubiquitin chains.  
 Expanding on the E4 concept, another U-box containing protein, CHIP was found 
to bind to the RING E3 ligase Parkin and expedite the polyubiquitination of its substrate - 
unfolded Pael Receptor (Pael-R) (67). Parkin polyubiquitinates unfolded Pael-R 
independently, but the levels of poly-Ub species are limited, and only a portion is 
selected for degradation by the proteasome. However, when Parkin, CHIP, and the CHIP 
cochaperone, Hsp70 are all present, rapid and efficient polyubiquitination occurs (67). 
CHIP U-box mutants and deletion of the U-box showed this extended poly-Ub activity to 
be CHIP-dependent. Therefore, the E4 moniker was also applied to CHIP. 
Shortly after the CHIP/Parkin observations were made, it was shown in C. 
Elegans that Ufd2 worked in concert with the E3 ligase CHN-1 (mammalian homologue 
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of CHIP) (68). While both Ufd2 and CHN-1 can catalyze monoubiquitination of the 
UNC-45 substrate on their own, efficient polyubiquitin chain elongation occurs only 
when both enzymes are present. It was shown that Ufd2 directly interacts with CHN-1 to 
promote this reaction. The N-terminal TPR and central coiled-coiled domains of CHN-1 
are necessary for this enhanced ubiquitination activity. The domain of Ufd2 necessary for 
CHIP interaction remains unknown. The Ufd2-CHN-1 interaction is also observed for 
mammalian homologues, E4B and CHIP, as determined in yeast two-hybrid screening 
(69). These observations support the proposal that these ligases possess so-called “E4” 
activity. Notably, the mechanism behind E4 activity has yet to be elucidated. It is also 
interesting to note that this activity is only necessary for higher eukaryotes as a CHN-1 
homologue does not exist in yeast.    
 
Structural Organization of Ufd/E4B 
 The 961 residue Ufd2 is composed of three domains: an N-terminal “variable” 
domain, a central armadillo-like repeat core domain, and the C-terminal U-box (43) 
(Figure 1.8A). The core and U-box domains are highly conserved throughout higher 
order eukaryotes. Despite being essential for several protein-protein interactions, the N-
terminus of Ufd2 is not conserved in mammalian species. Overall, the structure of Ufd2 
is highly α-helical and spans ~146 Å in length, ~84 Å in height and ~70 Å in width  
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(Figure 1.8B). The N-terminus and core domains comprise a contiguous, elongated yet 
globular unit with a short linker to the U-box domain. The flexible tether presumably 
allows the U-box to move freely in solution with respect to the rest of the protein (43).  
Two mammalian isoforms of Ufd2 are known, termed E4A and E4B. E4B 
appears to be the most physiologically relevant of the two, while little is known about 
Figure 1.8. Domain organization of Ufd2/E4A/B. A) Sequence conservation of the 
different homologues of Ufd2/E4A/B between Saccharomyces cerevisiae, Mus musculus, 
and Homo sapiens. B) Cartoon representation of the crystal structure of scUfd2 (2QIZ 
(43)).  
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E4A. Genetic studies reveal the importance of E4B in pathways such as Wallerian 
degeneration, cardiac muscle development, and various instances of neurological 
regulation (70-72). The focus in this dissertation is on the E4B isoform. 
 
The role of Ufd2 in ERAD 
The N-terminus of Ufd2 is a protein-protein interaction module. One of its 
binding partners is the nucleotide excision repair protein, Rad23, which plays important 
roles in both DNA damage repair pathways as well as in proteasome shuttling (73). 
Rad23 is a multi-domain protein comprised of a Ubiquitin Like (UBL) domain and two 
UBA domains. As previously described, Rad23‟s UBA domains recognize and interact 
with the specific structural motif between K48 and G76 of a Ub
K48
 polyubiquitin chain 
(74).  Through an unknown mechanism, Rad23 is recruited to the 26S proteasome where 
several subunits of the 19S cap bind to the UBL domain. The Rpn1, Rpn10, and Rpn13 
subunits all appear to be involved in Rad23 and Dsk2 binding (75, 76). Ufd2 also 
interacts with Rad23‟s UBL domain, but the exact purpose of this association remains 
unknown. However, it is speculated that Ufd2 may act as a triage factor and 
polyubiquitinate proteins that cannot be refolded by the heat shock response (HSR). After 
functioning in polyubiquitin chain elongation, Ufd2 facilitates the transfer of the newly 
polyubiquitinated species to Rad23 for transport to the proteasome. Recently, structures 
of Ufd2 in complex with the UBL domains of both Rad23 and Dsk2 were reported (73). 
These structures highlight a novel UBL-interacting domain in the Ufd2 N-terminus. The 
UBL domain of Dsk2 contains only approximately 30% sequence identity to Rad23, but 
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both bind to the same face of Ufd2. The Rad23 and Dsk2 UBL domains utilize slightly 
different residues to interact with Ufd2.    
Intriguingly, the N-terminus of Ufd2 is not conserved in its mammalian 
homologue, and it remains to be seen whether or not E4B interacts with the either of the 
mammalian Rad23 homologues, HR23A or HR23B. Another protein containing both 
UBL and UBA domains is Dsk2. Dsk2 functions in the proteasome shuttling pathway in 
the same fashion as Rad23. Like Rad23, the molecular mechanism underlying for handoff 
to the proteasome is unknown.  
The substrate binding domains of neither Ufd2 nor E4B have been characterized.  
Approximately 50 residues immediately preceding the U-box domain of Ufd2 are 
necessary to interact with the homohexameric AAA+ ATPase Cdc48 (77). Ufd2 
interaction with Cdc48 plays a vital role in ERAD of unfolded substrates, and thus Cdc48 
may act as a scaffolding protein to recruit substrates for Ufd2 poly-ubiquitination. Cdc48 
appears to function as a mediator between substrate recruiting and substrate processing at 
the ER-membrane level. A Ufd1/Npl4 heterocomplex (Cdc48
Ufd1/Npl4
) stimulates Cdc48 
binding to Ufd2, activating Ufd2 polyubiquitination chain elongation (77). When Ufd2 
generates a Ub
K48
 chain of sufficient length (generally ≥ 4 Ub moieties), substrates are 
targeted for proteasomal degradation. Interestingly, when Cdc48 associates with Ufd2 it 
restricts the length of the polyubiquitin chains on the substrate. However, these shorter 
polyubiquitin chains do not inhibit substrate recognition  
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by Rad23 or Dsk2, and degradation by the proteasome is observed. Thus, the purpose of 
chain length restriction by Cdc48 on Ufd2 remains unknown. 
 
Experimental Approach 
 Nuclear Magnetic Resonance (NMR) Spectroscopy 
  Much of the research accomplished in this dissertation involved NMR 
spectroscopy. NMR is a powerful tool for structural and biochemical analysis of 
biological macromolecules. NMR is commonly used for identification of inter-molecular 
interactions, determination and analysis of three-dimensional molecular structures, and 
measuring motional dynamics (78, 79). The NMR phenomenon arises from alignment of 
nuclear spins in a magnetic field. Electromagnetic pulses can then be applied to scan for 
resonance, and in turn measure certain physical properties of the observed atomic nuclei. 
The ability to simultaneously probe specific properties at the atomic level for multiple 
nuclei arguably makes NMR spectroscopy the most powerful method for biochemical 
analysis.  
     When performing NMR experiments on protein systems, 
15
N and 
13
C enrichment 
is used for observation of nitrogen and carbon nuclei, respectively. This is accomplished 
producing protein by overexpression in bacterial cells. Use of defined media with 
isotopically enriched nitrogen and/or carbon sources during growth provides a robust 
approach to produce isotopically enriched protein.  
  The most common NMR experiment used for this thesis work is the 2D 
15
N-
1
H 
Heteronuclear Single Quantum Correlation (HSQC) experiment. This experiment 
measures the spectral frequencies of 
15
N-
1
H amide pairs within the protein. A well-
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dispersed spectrum enables the resonances of the entire amino acid backbone to be 
observed.  Monitoring the backbone resonances is often sufficient for identification of 
molecular interactions as well as determining protein behavior under different 
experimental conditions. This chemical shift perturbation approach using 
15
N-
1
H HSQC 
experiments has been used extensively to measure the change in environment of a 
protein‟s backbone in the presence of a binding partner. In this scenario, the observed 
molecule is enriched with 
15
N while the ligand of interest is not. Therefore, only 
information about the protein of interest is observed. The ligand is titrated in at various 
concentrations, and the perturbations in chemical shifts can be measured. Unlike other 
binding measurements such as fluorescence or isothermal titration calorimetry, 
information obtained from NMR chemical shift perturbation experiments can be 
correlated directly to specific atoms in the protein. This provides a powerful method to 
map the binding site on the structure of the protein (80). In the case of protein-protein 
interactions, reciprocal experiments may be able to be collected in which the 
15
N-
enrichment is switched from one protein to the other, thus allowing for binding site 
mapping on both species of the interaction, and generation of high quality models of the 
complex (see Chapter II).  
  In order to correlate information about which resonance peak corresponds to 
which residue of the protein, a series of experiments to assign the resonances are 
necessary. A standard set of five triple resonance experiments generally allow for the 
direct assignment of the backbone resonances of a protein: HNCACB, CBCACONH, 
HNCA, HNCO, and HNCOCA (78). These experiments require isotopic enrichment in 
both 
15
N and 
13
C. 
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  For structural determination of a protein, complete side chain resonances must be 
identified and assigned as well. In regards to the structure determination in this thesis, 
this was accomplished through the double and triple resonance multi-nuclear experiments 
HBHACONH, (H)CC(CO)NH, and H(CC)(CO)NH, plus a homonuclear 
1
H-DQF-COSY 
experiment to assign aromatic side-chain resonances. The information from the combined 
backbone and side chain assignments was then applied to 2D and 3D Nuclear Overhauser 
Effect (NOE) experiments. These NOE-experiments offer information about important 
dipolar (through space) couplings, which characterize the spatial relationships between 
the H atoms. 
  With NOE data in hand, structure calculations were executed by use of the 
automated computational software CYANA. Through a series of algorithms, CYANA 
calculates the 3D orientation of the H atoms in the protein (81). To ensure correct 
chemical geometry, additional refinement was performed using restrained molecular 
dynamics and simulations in the AMBER force field (82). Coupled together, these 
methods allow for generation of highly useful, atomic resolution protein structures.  
 
 Mass Spectrometry 
  Recent advances in Mass Spectrometry technology have enabled the study of 
multi-protein complexes. These studies are most commonly undertaken using 
Electrospray Ionization Mass Spectrometry (ESI-MS), this ionization technique can be 
adjusted to allow non-covalent protein interactions to remain intact (83). When non-
covalent protein-protein interactions are left intact, ESI-MS is useful in verification of the 
stiochiometry of higher order protein complexes, including oligomerization. Despite the 
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transition from solution to the gas phase, these non-covalent complex species can be 
observed providing important biochemical data.  
   
Analytical Ultracentrifugation 
  Analytical Ultracentrifugation has emerged as a powerful tool for the biochemical 
analysis of macromolecular molecules and molecular assemblies. AUC is most often used 
to study the hydrodynamic properties of a macromolecule in solution. Two distinct types 
of AUC experiments are routinely used: sedimentation velocity (SV) and sedimentation 
equilibrium (SE) (84). In the context of this thesis, SV experiments were applied to study 
the oligomeric state of the U-box domain of E4B.  
SV experiments apply high centrifugal speeds to the sample, and optical dectors 
are used to monitor the redistribution of the sample from the top of the meniscus of the 
sample cell to the bottom of the sample cell over time (85, 86). The rate of movement of 
the molecule will vary based on its size and shape, and analysis of this data leads to 
determination of the overall oligomeric state or stoichiometric ratios of the molecule or 
molecular assembly under study. Determining oligomeric states as well as stoichiometric 
ratios in the context of protein assemblies provides valuable information on the 
biochemical basis for function.  
Running an SV experiment requires a two-chambered sample cell. One chamber, 
or sector, contains the molecule of interest in solution, while the other sector contains the 
reference solvent. The concentration distribution of the sample as it moves through 
solution under centrifuge is monitored over time and fit by the software package, SedFit 
(84, 86). A sedimentation coefficient is determined from this concentration distribution 
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using the equation s = ν / (ω2r) = Mb / f, where ν is the volume of the particle, ω the rotor 
speed, r the distance from the center of the rotor, Mb the buoyant molar mass and f the 
frictional coefficient (84, 86). 
  SV AUC experiments are used to determine the sedimentation coefficient for the 
sample of interest, whether it is a single protein species or a multi-protein complex. Two 
important parameters that can be determined from SV experiments are the frictional ratio 
and Stokes radius (f/fo and Rs, respectively). The frictional ratio provides information 
about the shape of the molecule: globular proteins have low frictional ratios while those 
proteins with overall elongated structures have high frictional ratios. The Stokes radius is 
the radius of a hard sphere that diffuses at the same rate as that of the molecule of 
interest.  
  
Research Summary 
  The research presented in this dissertation attempts to enhance our understanding 
of the cellular roles of E4B through both structural and functional analysis. The initial 
objective of E4B study was to identify its role in CHIP mediated polyubiquitination as 
well as to characterize interactions and analyze functions of its U-box domain with E2 
enzymes. To assess CHIP-E4B binding, recombinant production of E4B was necessary. 
However, attempts to produce the full length, recombinant E4B from Mus musculus in 
Eschericia coli did not pan out, and thus shorter, stable U-box containing domains of this 
protein were sought to focus on E2 interactions.  
To fully characterize E4BU-E2 enzyme interactions, structural determination of 
E4BU was necessary. After several attempts at E4BU crystallization, the structure was 
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determined via NMR spectroscopy and the interaction with the cognate E2 enzyme, 
UbcH5c was investigated using a combination of 
15
N-
1
H NMR chemical shift 
perturbation experiments and with the computational docking program, HADDOCK (87).    
  Oligomeric states of several U-box type E3 ligases play vital roles in their 
function (53, 54). Therefore, the oligmeric state of E4BU was assessed. Using a 
combination of Size Exclusion Chromatography coupled to Multi-Angle Light Scattering 
(SEC-MALS), Analytical Ultracentrifugation (AUC), and Electrospray Ionization Mass 
Spectrometry (ESI-MS), it was determined that E4BU is monomeric in solution. Based 
on this surprising information, the ligase function of E4BU was verified with an in vitro 
autoubiquitination assay. From these results, it was shown that monomeric E4BU is a 
fully functional E3 ligase. This work is discussed in depth in Chapter II. 
  The third chapter of this thesis describes research focused on understanding the 
dynamics of the E4BU-E2~Ubiquitin complex and indentifying how E4BU activates Ub 
release from the covalently bound E2. This portion of the research was completed as part 
of an extraordinary collaboration with Rachel Klevit‟s laboratory at the University of 
Washington. Our focus was on assessing the molecular motion of E2~Ub and how it is 
affected by E3 interactions and is discussed in Chapter III .  
  Using a stable UbcH5~Ub conjugate complex, chemical shift perturbation 
experiments were performed with E4BU. In addition, Ub resonances on the E2~Ub 
conjugate were monitored for changes induced by the binding of E4BU. From this 
information, several key residues were identified that appear to play a significant role in 
Ub activation by E4BU. Mutations were made on these residues and in vitro 
ubiquitination assays were performed to validate the presence of an allosteric network 
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necessary for Ub release from UbcH5 upon E4BU binding. Residual dipolar coupling 
NMR experiments were used to more accurately assess the flexibility of Ub in the 
presence and absence of E4BU. Interestingly, no change in Ub flexibility appears to be 
observed in the presence of E4BU, but more experiments must be completed to generate 
unambiguous conclusions.  
  Chapter IV summarizes the work completed on the U-box domain of E4B, 
discusses the impact and implications of these results, and assesses future studies 
necessary to further elucidate both structural and functional questions about E4B. 
Therapeutic implications of this research are also described. Taken together, this work 
provides critical insight into the structure and function of the monomeric U-box domain 
from E4B as well as its role in activating ubiquitin release from UbcH5. 
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CHAPTER II 
 
STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF THE MONOMERIC U-BOX DOMAIN 
FROM E4B
1
 
 
Introduction
 
Ubiquitination is a critical post-translational modification shown to target proteins 
in a variety of cellular signaling contexts, including transcriptional activation, 
endocytosis, DNA repair, and proteasomal degradation (1, 88-90). The molecular 
mechanism underlying the transfer of ubiquitin (Ub) to a substrate consists of three key 
enzymatic steps. First, ubiquitin itself is adenylated at its C-terminal glycine residue by 
an activating enzyme (E1). Second, the adenylated Ub forms a covalent linkage to a 
conjugating enzyme (E2). Finally, a ligating enzyme (E3) recruits both the Ub-charged 
E2 species and the target substrate protein.  Co-localization of the charged E2 and the 
substrate catalyzes the transfer of Ub to an ε-amine group on  a lysine residue of the 
target protein (89).  
 There are three classes of E3 enzymes:  HECT, RING, and U-box, which are 
distinguished on the basis of their E2-recruiting domains.  Whereas HECT and RING 
domain E3 ligases have been studied extensively, much less is known about the U-box 
proteins. The U-box and RING classes of E3 ligases act as scaffolding molecules that 
recruit and co-localize both a Ub-charged E2 and the substrate concomitantly. The 
 
1The bulk of this chapter was published in Nordquist et al., (2010) Structural and functional 
characterization of the monomeric U-box domain from E4B. Biochemistry. Jan 19;49(2):347-55. 
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 recruitment of substrate in these proteins involves protein interaction modules such as a 
WD-40 repeat, TPR and armadillo repeat domains (62, 91, 92).  
In addition to a common organization, the architecture of U-box and RING 
domains are similar.  Both contain a central alpha helix flanked by two surface exposed 
loops arranged in a cross-brace formation. The structure of RING domains is built around 
two zinc binding sites that are critical to its stability. In contrast, U-boxes do not bind 
zinc, but have evolved instead networks of hydrogen bonds and salt bridges in 
corresponding locations in the structure (60). Other similarities between these two 
domains include an antiparallel -sheet type arrangement involving the first surface 
exposed loop and the central alpha helix. The -sheet is stabilized by highly conserved 
hydrophobic residues responsible for the core packing and stability of the molecule. It has 
been reported that the L1 – 1 – L2 motif of U-box and RING domains are critical 
elements for E2 interactions (12, 53, 93). Most U-box and RING domain structures also 
contain an elongated C-terminal helix. The physical basis and physiological rationale for 
evolving distinct U-box and RING E3 ligases are not yet known.  
U-box proteins constitute a unique class of E3 ubiquitin ligases that appear to 
function in association with heat shock proteins in protein folding, refolding or complex 
formation. Ufd2 was first recognized as a U-box containing protein by Koegl and 
colleagues who designated the protein as an E4 ubiquitin ligase because it was shown to 
catalyze the elongation of previously ubiquitinated substrates (66). Ufd2 plays a role in 
the Cdc48 chaperone pathway. Ufd2 ubiquitinates Cdc48 clients targeting them for 
proteasome mediated degradation. Interactions have been reported between Ufd2 and 
Cdc48, and this interaction is stimulated by Cdc48 binding with its cofactors Npl4 and 
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Ufd1 (77). Additionally, the proteasome shuttling protein, Rad23 binds Ufd2 through its 
UBL domain, implicating Ufd2 in proteasome shuttling (94). It has yet to be determined 
if these interactions are conserved for the mammalian homolog E4B.   
In addition to the ability to interact with E2 enzymes, it was also found that Ufd2 
could interact with other E3 proteins, including another member of the Ufd family, Ufd4. 
Ufd4 is a HECT E3 ligase that was shown to only monoubiquitinate the UNC-45 
substrate. However, together with Ufd2, Ufd4 stimulates rapid and efficient substrate 
poly-ubiquitination. Ufd2, and its mammalian homologue, E4B, have also been reported 
to interact with another U-box containing protein, CHIP (68, 69). It appears that this 
interaction also promotes an increased rate of substrate poly-ubiquitination. 
An X-ray crystal structure of Ufd2 has been determined (43). The structure 
reveals three domains: an N-terminal variable domain, a conserved central armadillo-like 
repeat, and a C-terminal U-box domain. The U-box and armadillo-like repeat domains 
likely serve for recruiting E2 and substrate, respectively.  The N-terminal domain 
probably serves in regulation of function.  Sequence alignment of the yeast Ufd2 
sequence with the mammalian E4B homologue shows a very high degree of conservation 
within the armadillo-like repeat domain and U-box region; however, the N-terminal 
region is not conserved, and in fact, the yeast protein is 212 residues shorter than the 
mammalian protein.  Differences in the putative regulatory domain are consistent with 
the more complex regulatory mechanisms in higher eukaryotes.  
 Our group has undertaken a comprehensive investigation of the structure and 
function of the U-box domain of mammalian Ufd2, E4B.  We began by examining the 
state of oligomerization of the E4B U-box and show that it exists primarily as a monomer 
36 
 
in solution under a range of concentrations.  The structure was determined in solution by 
NMR and chemical shift perturbation experiments were used to map the interaction with 
the E2 enzyme UbcH5c.  This data was then used to generate a model of the complex.  
We also show the U-box alone is fully active in an in vitro autoubiquitination assay.   
 
Results 
To produce a stable E4B U-box domain, three C-terminal bacterial expression 
constructs were designed based on analysis of predicted secondary structure and 
comparison to the x-ray crystal structure of Ufd2: Ile1072-His1173, Val1082-His1173, 
and Ala1092-His1173. To determine the optimal construct for structural and biophysical 
analysis, all three constructs were expressed and purified with uniform 
15
N enrichment 
then characterized by 
15
N-
1
H-HSQC NMR. The constructs exhibited similar spectra with 
the same group of well-dispersed signals, but with a progressively larger number of 
signals in the central region of the spectrum in proportion to the length of the construct 
(Figure 2.1). This observation indicated all constructs contained a common globular 
domain but that the region Ile1072-Ala1092 lacks stable structure.  Moreover, the two 
longer constructs degraded over time, as evident from the appearance of heterogeneity in 
HSQC spectra acquired one week after the samples were first prepared. Consequently, all 
further NMR experiments were performed on the shortest construct, Ala1092-His1173, 
which will be referred to as E4BU. 
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Figure 2.1. 
15
N-
1
H HSQC NMR spectra of three E4B U-box domain constructs: (A) 
E4B(1072-1173), (B) E4B(1082-1173), and (C) E4B(1092-1173). As the construct 
increases in length at the N-terminus, overlap in the 8.0-8.5 
1
H p.p.m. region of the 
spectra significantly increases but no additional dispersed peaks outside this region are 
observed, indicating that residues 1072-1092 are unstructured. 
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E4BU is a monomer in solution 
All U-box E3 ligases characterized to date are single chain proteins that form 
homooligomers, except for the yeast homolog of E4B, Ufd2 (43, 53, 54, 95, 96). During 
the purification of E4BU, the protein was found to elute as a dimer with an apparent 
molecular weight of approximately 21 kDa according to size-exclusion chromatography 
(SEC) experiments. However, since molecular weight is notoriously difficult to quantify 
by SEC, additional experiments were performed to directly determine the oligomerization 
state of E4BU. The approaches included SEC-MALS, which indicated an ~10 kDa 
species in the primary peak (data not shown) and native mass spectrometry using 
electrospray ionization, which revealed a 10:1 ratio of monomer to dimer (Figure 2.2A). 
The predominance of monomer over dimer was further confirmed by analytical 
ultracentrifugation sedimentation velocity experiments, which also showed a 10:1 ratio of 
monomer over dimer (Figure 2.2B). Concentration-dependent NMR chemical shifts 
provide an additional sensitive indicator of self-association. 
15
N-
1
H HSQC spectra were 
acquired for 0.10 mM and 1.0 mM samples of 
15
N-E4BU and no difference was observed 
between the two spectra (Figure 2.3), indicating no significant population of dimer or 
higher aggregates even at the higher protein concentration.  
 
NMR Structure Determination of E4BU 
A high resolution solution structure of E4BU was determined by 
multidimensional heteronuclear NMR spectroscopy using isotopically enriched protein 
samples. A total of 1565 NOE-derived distance constraints and 92 dihedral angle 
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Figure 2.2. Characterization of self-association of E4BU. (A) Electrospray ionization 
mass spectrometry of E4BU. All ions detected correspond to monomeric species, 
except for a single additional (+9) charge state corresponding to a dimer (insert). All 
mass-to-charge (m/z) species correlate to a monomeric protein. (B) Analytical 
ultracentrifugation of a  100 µM solution of E4BU.  The results of the sedimentation 
velocity experiment yielded ~87% of monomer and < 9% of dimer. The remaining 
protein appears to form higher order aggregates.    
 
 
Figure 2.3. 
15
N-
1
H HSQC of E4BU collected at 100 µM (A) and 1 mM (B). 
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Figure 2.4. Solution NMR structure of E4BU.  (A) Stereo view of the final ensemble 
of 20 conformers representing the structure. (B) Comparison of E4BU with the U-box 
domain of Ufd2 extracted from the crystal of the intact protein.  Best-fit superposition 
of the two structures gives an rmsd over all backbone atoms of 1.15 Å. 
constraints were used as input for structure calculations.  The input constraint list was 
refined by using iterative cycles of CYANA. The final ensemble of 50 CYANA starting 
structures was further refined by restrained molecular dynamics in AMBER. The final 
representative ensemble consists of the 20 conformers selected on the basis of lowest 
restraint violation energy (Figure 2.4).  The structured region of the ensemble (residues 
1096-1170) has a final rmsd versus the mean of 0.45 Å for the backbone and 1.13 Å for 
all atoms. The high quality of the structure is reflected in the results from PROCHECK 
analysis. For example, 99% of all backbone torsion angles occupy the most favored and 
favored regions of the Ramachandran plot. Further details, and structural statistics are 
reported in Table 2.1. 
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The structure of E4BU consists of the ββαβα-fold typical of U-box and RING 
domains (Figure 2.4). The central α-helix is flanked by two prominent surface exposed 
loop regions, spanning residues Arg1104 to Thr1110 (L1) and Thr1138 to Gln1144 (L2). 
The characteristic network of hydrogen bonds within each loop stabilizes the overall 
structure. Critical polar contacts exist throughout L1. For example, the side chain of 
Arg1104 hydrogen bonds to the backbone carboxyl group of Asp1109. The side chain 
carboxyl group of Asp1105 is distinctive, forming a hydrogen bond to the backbone 
Table 2.1. Structural statistics for the solution NMR structure of the U-box domain of 
E4B.  
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amide of Leu1107 in 16 out of 20 structures of the ensemble. Of these 16, 10 show a 
bifurcated hydrogen bond to the amides of both Leu1107 and Met1108.  L2 contributes to  
a network of interactions similar to that involving L1. Important stabilizing hydrogen 
bonds include two from the carboxyl side chain of Asp1139: one oxygen atom hydrogen 
bonds to the backbone amides of Phe1141 and Asn1142 and the other interacts with 
Gln1144. Both of these interactions are observed in all 20 structures of the ensemble. 
Asp1139 appears to play a central role in the stabilization network as its backbone amide 
also is involved in a hydrogen bond with the side chain of Arg1143. This stabilizing bond 
is also seen in all 20 structures of the ensemble.  
 
Comparison of E4BU to other U-box and RING domains 
 Overall, the structure of E4BU has a high degree of structural similarity to other 
U-box and RING domains. An overlay of the backbone atoms of E4BU with the U-box 
domain of Ufd2 extracted from the crystal structure of the full protein (2QIZ) is shown in 
Figure 2.4B. The two structures superimpose with a backbone rmsd of 1.2 Å. Overlays 
with CHIP U-box, Prp19 U-box, and BRCA1 RING domains give rmsds of 1.3 Å, 1.4 Å, 
and 1.3 Å, respectively.  
 In order to obtain insights into the differences between monomeric E4BU and the 
dimeric U-box and RING domains, the sequence was analyzed by multiple sequence 
alignment. Two residues in the E4B U-box domain sequence were found to diverge 
significantly from the other U-boxes: Arg1117 and Glu1152, which are hydrophobic 
residues in all other U-boxes (Figure 2.5A, black arrows). In scPrp19 and mmCHIP, the 
residues corresponding to Arg1117 (Leu15 and Ile246, respectively) make crucial 
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hydrophobic contacts across the dimer interface (53, 54). The critical importance of this 
residue was shown for Prp19; mutation of Leu15 abrogated dimerization and abolished 
cell viability (54). The residues corresponding to Glu1152 in E4B are also hydrophobic in 
Prp19 and CHIP, and have been previously described as critical elements in the 
hydrophobic core and across the dimer interface. Analysis of the electrostatic surface 
potential of U-box domains reveals that E4BU is significantly more acidic than the Prp19 
and CHIP U-boxes, especially in the region corresponding to the dimer interface (Figure 
2.5B-D). In particular, E4BU Glu1152 is responsible for a highly negative patch at the 
core of what would be the dimer interface. Hence, electrostatic repulsion at the dimer 
interface due to substitution of hydrophobic residues with charged side chains appears to 
significantly destabilize the dimeric state of E4BU. 
 
E4BU – UbcH5 interaction 
U-box and RING domains serve as E2-recruiting modules in E3 ubiquitin ligases. 
To determine how E4BU interacts with E2 enzymes, the binding interface between the U-
box domain of E4B and a cognate E2 enzyme UbcH5c was analyzed using NMR 
chemical shift perturbation experiments. UbcH5c was used for these experiments since 
the backbone NMR assignments and the crystal structure were already available (P. 
Brzovic and R. Klevit, unpublished; PDB ID 1X23). Titration of UbcH5c into 
15
N-
enriched E4BU was monitored in 
15
N-
1
H HSQC spectra acquired at molar ratios of 
1:0.125, 1:0.25, 1:0.5, 1:1, and 1:2. Distinct chemical shift perturbations were observed 
for specific peaks even at the lowest titration point (Figure 2.6A). Over the course of the 
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 Figure 2.5. E4BU has a more negative surface potential than other U-box 
domains. (A) Multiple sequence alignment of E4BU with Ufd2, CHIP, and Prp19. 
Alignments made using the CLUSTALW server at EBI (97). The resulting alignment file 
was then processed through ESPript (98). (B) Electrostatic surface representation of the 
U-box dimer interface of E4BU. Blue coloring corresponds to positive charge and red 
corresponds to negative charge. (C) Electrostatic surface representation of the Prp19 U-
box dimer interface. (D) Electrostatic surface representation of the CHIP U-box dimer 
interface.  The electrostatic fields were calculated using the Adaptive Poisson-Boltzmann 
Solver algorithm for electrostatics (99). 
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titration a significant number of peaks broadened beyond detection as a consequence of 
formation of the 27 kDa complex, and/or effects associated with intermediate exchange 
on the NMR timescale. Overall, the resonances of 10 residues were significantly 
perturbed (mean + 1 standard deviation): Leu1107, Met1108, Asp1109, Leu1118, 
Thr1122, Ile1129, Leu1130, Arg1131, Asn1135, and Asn1142 (Figure 2.7). Using the 
backbone assignments for E4BU, the perturbed residues were then mapped onto the 
structure (Figure 2.6B). It has previously been reported that Ile235 in CHIP and the 
corresponding residue in BRCA1, Ile26, are crucial for interaction with E2 (93); the 
corresponding residue in E4BU, Leu1107, has one of the largest chemical shift 
perturbations, upon binding of UbcH5c. Overall, the perturbed residues are found to be 
located in and around the two surface exposed loops, including residues in the central α-
helix, α1, consistent with the location of E2 binding sites in other RING and U-box 
domains.   
Reciprocal titrations were also performed using unlabeled E4BU and 
15
N-UbcH5c 
with spectra acquired at ratios of 1:0.063, 1:0.125, 1:0.25, 1:0.5, 1:1, and 1:2. In all, 14 
residues were significantly perturbed including: Arg5, Ile6, Asn7, Lys8, and Ser11 in α1; 
Thr58, Asp59, and Phe62 in L4; Ser94, Ala96, Leu97, and Ile99, in L7; and Ile88 and 
Leu103 in helical regions that flank L7 (Figure 2.6C).  When mapped out on the structure 
of UbcH5c, these residues form a contiguous surface on one face of the protein (Figure 
2.6D).  These results are consistent with previous reports of E2 interactions with CHIP 
(13, 14, 32).  
 In order to gain a more thorough understanding of the interface between E4BU 
and UbcH5c, the chemical shift perturbation data was used with HADDOCK to generate 
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Figure 2.6. NMR chemical shift perturbations indicating interaction of E4BU and 
UbcH5c. (A) 
15
N-
1
H HSQC spectra of E4BU obtained in the absence (black) and 
presence (red) of   0.125 molar equivalent of UbcH5c. (B) Surface representation of 
E4B with residues that have significant chemical shift perturbations highlighted in red. 
(C) 
15
N-
1
H HSQC spectra of UbcH5c in the absence (black) and presence (red) of  
0.125 molar equivalent of E4BU. (D) Surface representation of UbcH5c with residues 
that have significant chemical shift perturbations highlighted in red. 
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 a molecular model of the complex. It has been previously demonstrated that using crystal 
structures in HADDOCK docking may not offer sufficient initial flexibility for proper 
docking (100).  A molecular dynamics simulation was therefore carried out to generate an 
ensemble of 20 UbcH5c structures.  Active residues for the HADDOCK ambiguous 
 
Figure 2.7. Plots of chemical shift perturbations showing interaction of E4BU with  
UbcH5c. (A) Unlabelled UbcH5c titrated into 
15
N-enriched E4BU. Perturbations 
greater than the mean plus one standard deviation are represented by the black bars. 
(B) Unlabelled E4BU titrated into 
15
N-enriched UbcH5c. Perturbations greater than 
the mean plus one standard deviation are represented by the black bars. 
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interaction restraints (AIRs) were assigned to residues exhibiting significant chemical 
shift perturbations (mean+1SD) or broadening and backbone and side chain regions that 
occupied greater than or equal to 50% solvent accessibility (as calculated by NACCESS).  
Overall, 7 active and 4 passive residues were assigned for the E4BU ensemble, while 6 
active and 7 passive residues were assigned for UbcH5c. Cluster analysis of the 200 
models generated by HADDOCK generated 9 groups of 4 molecules or more. However, 
of these, two similar clusters stood out as being highly populated (Cluster 1- 54 
conformers, Cluster 2- 16 conformers) and having the most favorable HADDOCK 
energies. The 20 lowest energy conformers of the most highly populated cluster were 
selected to represent the model of the complex. This model contains interactions between 
L1 of E4BU and α1 of UbcH5c, α1 of E4BU and L4 of UbcH5c, and L2 of E4BU and L7 
of UbcH5c (Figure 2.8). Remarkably, this model aligns extremely well with the co-
crystal structure of UbcH5a and the CHIP dimer, superimposing to an rmsd of only 
0.81Å. Thus, this experimentally–guided model suggests monomeric E4BU binds E2 
conjugating enzymes in the same manner as U-box and RING domain dimers.  
 
E4BU function 
We next asked whether or not the monomeric E4BU is functional, as interaction 
with an E2 is not sufficient to prove activity. Most E3 ligases are able to modify 
themselves through autoubiquitination, where the ligase itself serves as the substrate, a 
process that serves a useful role in auto-regulation through protein turnover.  Because the 
E4B(1092-1173) construct encodes just the U-box domain, the longer 1072-1173  
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construct was used for the autoubiquitination experiments.  The additional 20 residues 
outside of the U-box domain, four of which are lysines, ensure there is an adequate 
substrate for ubiquitination. The E4BU in vitro autoubiquitination assay was developed 
based on our protocol [Y.N.D. and W.J.C., unpublished results] using recombinant 
bacterially expressed and purified proteins Uba1 (E1), UbcH5 (E2), E4B(1072-1173) 
(E3/substrate), and Ub.  Analysis of the autoubiquitination reaction by SDS-PAGE 
Figure 2.8. Model of the complex of E4BU and UbcH5c based on NMR chemical shift 
perturbations. Ribbon diagram of the mean structure from the 20 lowest energy 
conformers of the highest populated cluster from HADDOCK calculations with E4BU 
(blue) and UbcH5c (salmon). 
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reveals time-dependent formation of higher molecular weight E4B species, showing that 
the U-box has robust autoubiquitination activity (Figure 2.9). 
 
Figure 2.9. Ubiquitination activity of the monmeric E4B U-box in an in vitro 
ubiquitination assay.  Time course of the assay using E3B(1072-1173) and the UbcH5c 
E2 conjugating enzyme. 
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Discussion 
We have shown that unlike other U-box proteins characterized to date, the U-box 
domain of E4B exists and functions as a monomer in solution (53, 54, 56). It could be 
hypothesized that the availability of two or more E2 binding modules in oligomeric E3 
ligases would increase the processivity of substrate ubiquitination through faster loading 
and unloading of E2 enzymes on the E3. However, this does not appear to be the case, as 
most oligomeric U-box and RING E3 ligases appear to possess only one active binding 
site. The clearest example of „half-of-sites‟ binding is the U-box protein CHIP.  The x-ray 
crystal structure of CHIP reveals a unique asymmetric dimer in which one of the U-box 
domains is blocked from interacting with E2 enzymes (53). 
The intrinsic dimerization of isolated U-box domains appears to be weak. In the 
case of Prp19, analytical ultracentrifugation revealed that the Prp19 U-box (Prp19U) has 
only a weak propensity to dimerize. The solution NMR structure of Prp19U was 
determined in a monomeric state at a concentration of 1 mM, but a dimer was formed 
when the protein was crystallized from a solution at more than 2-fold higher 
concentration. A central coiled-coil domain adjacent to the U-box domain is the dominant 
oligomerization interface, leading to an overall tetrameric assembly (62). The short tether 
to the coiled-coil domain results in a very high local concentration of pairs of U-boxes in 
the tetramer, which drives U-box/U-box dimerization in vivo (54). The U-box domain of 
CHIP (CHIPU) exhibits similar properties. For example, isolated CHIPU crystallizes as a 
dimer (93). However, like Prp19, the U-box is not the dominant oligomerization domain, 
but rather, it is the central coiled-coil region of the protein (53, 96). Our studies showed 
E4BU has a very weak propensity to dimerize. Moreover, it has been resistant to 
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crystallization. It appears that oligomerizatin of E4BU would require an additional 
oligomerization domain in order to dimerize. However, dimerization of E4BU seems 
unlikely even in the context of oligomerization of the full-length protein due to the 
charged residues present in the common U-box domain dimerization interface. Thus, the 
E4B U-box E3 ligase stands out for its structure and apparent function in a monomeric 
state. 
Previous reports have suggested that E4B interacts with CHIP in regulation of the 
myosin assembly pathway in C. elegans (69). The TPR domains of CHIP are required for 
interaction with E4B, but the corresponding region of E4B necessary for CHIP binding is 
not yet known (68). CHIP is a dimer and it is intriguing to consider the possibility that it 
forms a hetero-oligomer with E4B and whether one or both E3 ligases are active in the 
complex, since CHIP exhibits „half of sites‟ binding, it would also be important to 
determine if U-box domains from one or both E3 ligases are able to bind E2 enzymes 
concomitantly. If a novel U-box hetero-oligomer were formed and it allowed E2 access to 
multiple U-box domains, the rates and relative processivity of substrate ubiquitination 
would likely increase.  
Despite the information noted above, the function of E4B is not well 
characterized and further study is required. For example, only UbcH5 family E2 
conjugating enzymes are known to function with the E4B U-box, but other E2 enzymes 
have not been tested. Evidence to date suggests E4B polyubiquitinates substrates leading 
to protein turnover (101), but more in-depth functional analysis is required to confirm 
this. Some clues can be obtained from characterization of the polyubiquitin chain 
topology of conjugates formed on E4B substrates, and such studies will be reported in 
53 
 
due course. The initial assignment of Ufd2 as an E4 ubiquitin ligase remains an open 
issue. Further analysis of E4B structure and biochemical properties will help and test and 
refine this hypothesis and generate a clearer understanding of the cellular activities of this 
unique monomeric ubiquitin ligase.  
 
Methods 
Expression Plasmids.  
 Mouse E4B DNA was amplified with overhanging 5‟ BamH1 and 3‟ Xho1 
restriction sites for subcloning into in-house pBG vectors (L. Mizoue; Center for 
Structural Biology, Vanderbilt University). Residues 1072-1173, 1082-1173, and 1092-
1173 were subcloned into the pBG102 vector, which produces an N-terminal 6xHis-
SUMO tag fusion protein. Human UbcH5c was produced as an untagged construct from 
pET28 as described previously (46).  
 
Protein Purification 
 The E4B U-box constructs as well as UbcH5c were overexpressed in BL21(DE3) 
Escherichia coli strains. The E4B proteins were purified by Nickel affinity 
chromatography and the His-SUMO tag was cleaved by H3C precision protease. A 
second purification step with the same column removed the affinity tag from the sample. 
The protein was further purified by anion-exchange chromatography using a SourceQ 
column and Superose6 gel filtration chromatography. UbcH5c was purified by cation 
exchange chromatography using SP resin, followed by size-exclusion chromatography 
with an S75 column.  The proteins were dialyzed against 20 mM TRIS at pH 7.0 and 50 
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mM NaCl and concentrated for further studies. Protein concentrations were determined 
by using a calculated extinction coefficient for each protein. Protein samples for NMR 
experiments were expressed in minimal media with NH4Cl and glucose as the sole 
nitrogen and carbon sources, respectively. 
15
NH4Cl and [
13
C6]glucose (Cambridge 
Isotope Laboratories) were used as needed to prepare the requisite isotopically enriched 
proteins.  
 
Electrospray Mass Spectrometry 
 Experiments were conducted with an ESI-oaTOF (electrospray ionization 
orthogonal accelerating time-of-flight) mass spectrometer (micrOTOF, Bruker Daltonics, 
Inc., Billercia, MA), which has been modified for enhanced collisional cooling in the 
source for the analysis of noncovalent protein complexes. This modification and methods 
have been previously described (102). E4B residues 1092-1173 was prepared at 
concentrations of 250 µM, 500 µM, and 1 mM in 25 mM sodium acetate at pH 7.0.  
 
Analytical Ultracentrifugation 
  The state of oligomerization of E4B was analyzed by sedimentation velocity 
analysis. Samples to be analyzed by AUC were first dialysed extensively against 20 mM 
TRIS buffer at pH 7.0 containing 50 mM NaCl, and dialysis buffer was saved to be used 
in the reference sector of each sample cell. AUC analysis was performed at 20 
o
C in a 
Beckman Optima XL-I analytical ultracentrifuge. Sample concentrations of 100 µM, 50 
µM, and 25 µM were loaded into standard 12 mm 2-sector Epon-charcoal cells, and 
housed in an An-60 Ti rotor. Sedimentation behavior resulting from a rotor speed of 
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50,000 rpm was observed using the optical absorbance of each sample at a wavelength of 
280 nm. The initial 200 scans obtained from each cell were fitted according to the 
continuous c(S) Lamm equation model in the SEDFIT software package (version 9.4) in 
order to obtain the relative prevalence of each oligomeric species (103). 
 
NMR Spectroscopy 
 NMR experiments were conducted using Bruker DRX 600 and 800 MHz 
spectrometers equipped with z-axis gradient TXI cryoprobes. The 
15
N-
1
H HSQC 
experiments to compare different E4B U-box constructs were acquired at 25 °C with 750 
M protein in 25 mM NaH2PO4 at pH 6.5, 25 mM NaCl, and 5% D2O.  To search for 
oligomerization-dependent changes in linewidth, 
15
N-
1
H HSQC experiments were 
acquired at concentrations of 100 M and 1 mM 15N-E4B(1092-1173) under identical 
conditions. 
To obtain backbone resonance assignments, 750 µM 
13
C,
15
N-E4B(1092-1173) 
was prepared in 25 mM NaH2PO4 at pH 6.5, 25 mM NaCl, and 5% D2O.  2D 
15
N-
1
H 
HSQC and 3D HNCACB, CBCA(CO)NH, HNCA, and HNCO experiments were 
conducted.  To obtain the side chain resonance assignments of E4B (1092-1173), the 
same sample was used to acquire 2D 
13
C-
1
H HSQC and 3D HCCH-TOCSY and HCCH-
COSY experiments.  The final resonance assignments were deposited at the Biological 
Magnetic Resonance Data Bank under entry 16623.  2D 
1
H-NOESY and 3D 
15
N-
NOESY-HSQC and 
13
C-NOESY-HSQC experiments were recorded to assign 
intramolecular NOEs.  All NMR data were processed using NMRPipe (104) and 
analyzed with Sparky (105). 
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The NMR chemical shift perturbation assays employed either 
15
N-E4BU and 
unlabeled UbcH5c or 
15
N-UbcH5c and unlabeled E4BU. The NMR samples contained 
100 µM 
15
N-protein in 25 mM NaH2PO4 at pH 7.0, 150 mM NaCl, and 5% D2O. 
Unlabeled protein in the same buffer was added to the labeled sample until the molar 
ratio reached 1:2 (
15
N labeled:unlabeled). The normalized chemical shift change was 
calculated using the equation Δσ = √[(ΔH)2 + (ΔN/5)2], where ΔH and ΔN are chemical 
shift changes in proton and nitrogen, respectively (106). 
 
Structure Calculations 
 Upper bounds for distance restraints were generated using the CALIBA module in 
CYANA (107). The reference volume determined by CALIBA was increased 5 times 
before conversion in order to loosen the distance restraints. Backbone torsion angle 
restraints for E4B (1092-1173) were estimated  from backbone chemical shifts using 
TALOS (108).  
The structural analysis involved multiple iterations of CYANA calculations and 
inspection of the restraints and the spectra.  NOEs were identified through a combination 
of manual and automatic assignments using CYANA. At each iteration, 100 structures 
were generated using CYANA. In the later stages, the 50 structures with lowest target 
function were selected for further refinement by restrained molecular dynamics (rMD) 
calculations in AMBER 9 with implicit treatment of the water solvent (82). After 1 ps of 
energy minimization to regularize CYANA structures in the AMBER force field, the 
temperature of the system was rapidly increased to 1200 K over 5 ps, then was slowly 
cooled to 0 K over 15 ps. NMR restraints were slowly turned on during the first 3 ps and 
57 
 
kept for the rest of the simulation. Force constants for distance and torsion angle 
constraints were set to 32 and 50 kcal/mol, respectively. To select the final representative 
ensemble of conformers, the structures were placed in order of increasing restraint 
violation energy and the top 20 were selected. The quality of the final ensemble was 
assessed using the Procheck-NMR and MOLPROBITY programs (109, 110). The final 
ensemble of 20 conformers was deposited at the Protein Data Bank under code 2KR4. 
 
Free Molecular Dynamics Simulation of UbcH5c 
 Using chain A of PDB ID 1X23, the first N-terminal 6 residues from the cloning 
vector were removed so as to not interfere with modeling. Initially, 500 steps of 
minimization over a period of 2 fs were run to allow relaxation of the initial structure. A 
1000 fs molecular dynamic simulation was run in which coordinates were extracted every 
50 fs, generating an ensemble of 20 structures. The molecular dynamics simulations were 
run in AMBER9 with the ff03 force field at a constant temperature of 300 K. The 
structure was solvated in a cubic box of TIP3P water using a minimum distance of 14 Å 
between the protein and solvent edges.  
 
E4BU-UbcH5c docking using HADDOCK 
 A model for the E4BU-UbcH5c complex was generated using HADDOCK2 (87). 
The four unstructured N-terminal residues of the E4BU construct were removed from the 
coordinate file so as to not interfere with docking of UbcH5c. The average solvent 
accessibilities per residue in the ensemble of E4BU and UbcH5c were calculated using 
NACCESS (111). Residues with a solvent accessible surface higher than 50% and 
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chemical shift perturbations more than 1 S.D. above the mean were designated as active 
for HADDOCK calculations. The adjacent residues with solvent accessibility greater than 
50% were designated as passive residues. In the first iteration of the calculation, an initial 
ensemble of 1000 rigid body docking models was generated. The 200 lowest energy 
models were selected for a second iteration with semi-flexible simulated annealing and 
these were further refined in explicit water. The ensemble of structures was generated 
using the final ensemble of 20 E4BU structures and 20 UbcH5c structures from a room 
temperature MD simulation in AMBER starting from the crystal structure of UbcH5c, as 
described above.  The 20 lowest energy models were selected from the most populated 
cluster with the lowest HADDOCK score and used for analysis.  
 
In vitro autoubiquitination assay 
Ubiquitination experiments were carried out at a final volume of 20 µl with E1 
(BostonBiochem) at 52 nM, bacterially expressed His6-E2-UbcH5a at 0.6 µM, ubiquitin 
(BostonBiochem) at 50 µM, and E4B 1072-1173 at 1 µM. The assay was performed in 
buffer containing 100 mM NaCl, 1 mM DTT, 5 mM MgCl2 and 25 mM Tris-Cl at pH 
7.5. The reactions were activated with 5 mM ATP and incubated at 30 
o
C for the different 
times indicated. To stop the ubiquitination reaction, the samples were incubated for 15 
minutes at 90 
o
C after the addition of 5 µl SDS-loading buffer. Reactions were resolved 
on a NuPAGE 4-12% Bis-Tris gradient gel (Invitrogen) and detected by a SimplyBlue 
SafeStain (Invitrogen). 
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CHAPTER III 
 
ADDRESSING ALLOSTERIC ACTIVATION OF THE E2~UB CONJUGATE USING THE E4B U-
BOX DOMAIN 
 
Introduction   
 Post-translational modifications propagate molecular signals critical for cellular 
viability. The small protein ubiquitin is one such modifier, which functions in a large 
number of signaling pathways. Ubiquitination proceedes via a series of three enzymes to 
target and attach to a substrate (40). While this process has been extensively studied, the 
full molecular details of how ubiquitin is activated and transferred to specific residues on 
the target substrate remain uknown (112). Full characterization of this mechanism is 
essential to understanding how the different enzymes act in concert to generate the 
diverse range of ubiquitin modifications and functional outcomes.  
Even though ubiquitin is a small and unremarkably globular protein, it has several 
unique characteristics (113). This in turn allows substrates to be modified by ubiquitin in 
several different ways and consequently, downstream signals can be quite diverse (6, 27, 
114, 115). The variety of ubiquitin signals arises in part because extended poly-ubiquitin 
chains can be built on any one of its seven lysine residues. The three-dimensional 
architecture of each of these chains is unique based on which lysine residues serve as the 
linker between molecules in the chain. The differences in architecture generate specificity 
for its function. Thus, different chain topologies have been linked to DNA repair 
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pathways (Ub
K63
), protein recruitment (Ub
K6
), and the benchmark signaling pathway - 
proteasome mediated degradation (Ub
K11
, Ub
K48
) (10, 27).   
 Ubiquitination occurs via the action of three different enzymes, termed E1, E2, 
and E3. E1 activating enzymes begin the process by adenylating the C-terminal glycine 
of ubiquitin, forming a thiolester bond between the C-terminus of ubiquitin and a cysteine 
located in the active site of the E1. Once E1 is covalently linked to Ub, it recruits an E2 
conjugating enzyme via an E2 binding domain and subsequently transfers Ub to the E2 
(41). E2 conjugating enzymes also utilize a cysteine residue to form a thiolester bond 
with the C-terminus of Ub. E3 ligases bind the E2~Ub conjugate as well as the substrate 
of interest, and catalyze the transfer of Ub from the E2 to the substrate.   
Two E1 enzymes modulate all ubiquitination activity in the mammalian system, 
and Uba1 appears to be responsible for an overwhelming majority of these events (44). 
Unlike the limited number of activating enzymes, there are currently 37 classified E2 
conjugating enzymes and over 600 genes thought to encode E3 ligases (27). While all E2 
enzymes contain a conserved catalytic fold domain, E3 enzymes are divided into three 
classes: U-box, RING, and HECT. HECT domain E3 ligases utilize a unique mechanism 
for Ub ligation, in which a cysteine residue accepts Ub from the E2~Ub conjugate. (59). 
RING and U-box type E3 ligases are structurally similar and make up the overwhelming 
majority of all E3 ligases in the proteome. U-box and RING E3s do not directly bind 
ubiquitin, and thus function as scaffolding-type catalysts that co-localize both the 
substrate and the E2~Ub conjugate to promote ubiquitination (116, 117). Hence, the Ub 
is transferred directly from the E2 enzyme to the substrate.  
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The mechanism by which Ub is transferred from RING or U-box bound 
conjugates to substrates remains a veritable black box: neither the mechanism for how Ub 
is released from the E2 nor how the activated Ub reaches the E3 bound substrate are 
known (118). Knowledge of these mechanisms will greatly enhance understanding of 
how different Ub~E2-E3 interactions propagate different Ub modifications. This in turn 
will inform the underlying basis for the pathophysiology of defective ubiquitination 
function.  
In this study, we have investigated the structure and dynamics of the E2~Ub 
conjugate formed by the monomeric U-box domain of E4B and the E2 enzyme, UbcH5c. 
NMR chemical shift perturbation experiments revealed differences in the E4BU 
structural interface with UbcH5c versus the interface with E4BU-UbcH5c~Ub. By 
monitoring NMR chemical shifts, the residues whose structural interface is altered have 
been identified.  Mutation of these residues either reduces or abrogates ubiquitin activity 
in in vitro ubiquitination assays. Together, this information provides new insight into the 
molecular mechanisms of E2~Ub activation, suggesting the existence of an allosteric 
network of residues essential to activation of the E2~Ub conjugate.  
 
Results 
Optimization of the stability of a model UbcH5~Ub conjugate 
To date, the only E2 enzymes shown to function with E4B have been from the 
promiscuous UbcH5 family. UbcH5a, UbcH5b, and UbcH5c all function with Ufd2 or 
E4B, and for the ease of these experiments, UbcH5c was chosen for this study (43, 66, 
119). An inherent problem in studying the characteristics of E2~Ub conjugates is the 
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labile nature of the native thiolester bond. To overcome this obstacle, we utilized a thiol 
conjugate analog that is produced when substituting the active site Cys85 with serine. As 
a result, reaction of Ub with the E2 produces a more stable oxyester bond (120). For 
example, the charged UbcH5c mutant (UbcH5m) has a long enough lifetime to be 
visualized by SDS-PAGE, whereas the charged native UbcH5c does not. When 
UbcH5m~Ub was incubated with increasing amounts of purified E4BU at pH 7.0 for 1 
hour at 25 °C, E4BU catalyzes the hydrolysis of Ub even with this more stable oxyester 
bond (Figure 3.1A). The hydrolysis of Ub from UbcH5m is a base catalyzed reaction, and 
thus the pH was optimized to prevent unwanted hydrolysis in the presence of E4BU. To 
this end, UbcH5m~Ub was incubated with equimolar amounts of E4BU at varying pH 
levels, and the extent of hydrolysis over the course of 66 hours was analyzed. pHs in the 
4-5 range effectively inhibit E4BU catalyzed UbcH5m~Ub hydrolysis during this period 
while a pH of 6 or greater does not (Figure 3.1B). For future experiments involving study 
of the UbcH5m~Ub conjugate, a pH of 5 was used to prevent ubiquitin release in the 
presence of E4BU.  
 
Ubiquitin conjugated to UbcH5 affects E4BU binding 
 Previously, NMR chemical shift perturbation analysis was used to map the 
interaction between free (unconjugated) UbcH5c and E4BU (119). Based on the 
observation that E4BU catalyzes the activation of Ub~UbcH5m, we examined the 
differences in chemical shifts of E4BU complexes with UbcH5c and the UbcH5m~Ub 
conjugate to determine if the covalent attachment of ubiquitin alters the way in which the 
two proteins interact.  
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Comparisons of the chemical shifts of E4BU in complex with UbcH5c alone and 
with the UbcH5m~Ub conjugate show there are subtle differences  (Figure 3.2). The 
residues of E4BU that are perturbed upon binding to UbcH5c are the same as those 
perturbed by the UbcH5m~Ub conjugate, indicating that the binding interface on E4BU 
does not appear to be altered by conjugation of ubiquitin. However, several of the E4BU 
residues are perturbed in a different manner when titrated with UbcH5c versus 
UbcH5m~Ub. Notably, the chemical shifts of Phe1141, Asn1142, and Arg1143 of E4BU 
are significantly different. For example, the chemical shifts of Phe1141 and Arg1143 of 
E4BU shift in different directions when titrated with UbcH5m~Ub versus UbcH5c alone. 
Additionally, the chemical shift perturbation of Asn1142 shows a decrease in intensity 
Figure 3.1. E4BU catalyzes Ub release from UbcH5m~Ub, but is inhibited at pHs 
below 6.0. A) UbcH5~Ub was incubated with increasing amounts of E4BU at pH 7.0 
for 60 minutes, and the extent of UbcH5 – Ub hydrolysis was monitored by SDS-
PAGE. B) UbcH5~Ub at varying pHs was incubated with an equimolar amount of 
E4BU, and the rate of hydrolysis was monitored at 16 and 66 hours by SDS-PAGE. 
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when titrated with UbcH5m~Ub versus UbcH5c alone.  Remarkably, these residues are 
located in the binding interface between E4BU and UbcH5, remote from the site of Ub 
attachment. Nevertheless, since their chemical shifts are different, these data suggest they 
play some role in the activation of the UbcH5m~Ub conjugate.  
The next step in our analysis was to determine if there are any unique effects on 
UbcH5m~Ub upon binding to E4BU. This involved analyzing the extent of chemical 
shift perturbations of UbcH5c and Ub upon binding to
 
 
 
Figure 3.2. The presence of Ub conjugated to UbcH5 causes changes in the interaction 
with E4BU. 
15
N-
1
H HSQCs of 
15
N-E4BU were collected in the absence (black) and 
presence of UbcH5 alone (blue) and UbcH5 conjugated to Ub (red). Changes in 
chemical shifts along the E4BU:UbcH5 binding interface are noted by arrows.  Data 
courtesy of Jonathan Pruneda.  
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E4BU. Hence both subunits of the conjugate were isotopically enriched with 
15
N and 
analyzed. As expected, the residues of UbcH5c previously known to have chemical shift 
perturbations when bound to E4BU, are also perturbed in the context of UbcH5m~Ub 
bound to E4BU, indicating that UbcH5m~Ub interacts with E4BU. Remarkably, 
however, several new residues exhibit small perturbations, indicating that there is a 
difference in binding between UbcH5c alone versus UbcH5m~Ub to E4BU (Figure 3.3). 
Remarkably, these new residues are not situated directly in the binding interface, but 
rather are located in what is referred to as the “cross-over” helix of the E2 – spanning 
residues 98 to 112. Effects on these residues are intriguing because of their proximity to 
the active site cysteine residue. Val102, Leu104, and Cys107 of UbcH5 all exhibit 
differences in chemical shift perturbations for the free E2 enzyme versus the E2~Ub 
conjguate. This observation suggests that E4BU binding to UbcH5m~Ub senses the 
presence of ubiquitin, at residues that are remote from the site of covalent Ub attachment.  
The effects on ubiquitin were also be analyzed by this approach. Surprisingly, 
several residues of ubiquitin in the UbcH5m~Ub conjugate undergo significant 
perturbations upon binding to E4BU, even though the binding site for the E3 ligase is 
remote from the site of covalent attachment. Of particular interest, Leu8 and Ile44 are 
both perturbed, and these constitute part of an essential Ub binding site. Therefore, it 
appears that interaction between E2~Ub and E4BU results in an allosteric change in 
ubiquitin. This finding is highly intriguing as such an allosteric effect could conceivably 
contribute to puzzling activation of the UbcH5m~Ub conjugate.  
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Figure 3.3. Effects of E4BU binding on 
15
N-UbcH5~
15
N-Ub conjugate. A) 
15
N-
1
H 
HSQC of free 
15
N-UbcH5c (black) titrated with an equimolar ratio of E4BU (red). B) 
15
N-
1
H HSQC of 
15
N-UbcH5m~
15
N-Ub (black) titrated with an equimolar ratio of 
E4BU (red). C) Residues of interest on UbcH5c (green) highlighted with sidechains in 
red. E4BU surface  shown in orange.  
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Testing the putative allosteric network  
 The chemical shift perturbation data suggest the existence of an allosteric network 
coupling binding of the E2 to the E3 ligase and activation of E2~Ub conjugate. In order 
to test the functional relevance of this putative allosteric network, we designed a series of 
mutations in Ub, UbcH5m, and E4BU and assayed their activity in in vitro 
autoubiquitination assays. Since the isolated U-box domain of E4B cannot undergo 
autoubiquitination, a construct with an additional 20 residues at the N-terminus was used 
for these reactions (E4BU20). Among these 20 residues are three lysine residues that 
have previously been shown to undergo autoubiquitination in a standard in vitro assay 
(Figure 2.9). For the mutational analysis, a total of eight mutations were made on six 
different residues in each of the three components of the complex (Table 3.1). E4B 
residues Phe1141 and Arg1143 have previously been shown to play a part in UbcH5 
PROTEIN MUTATION 
E4BU F1141A 
E4BU R1143A 
UbcH5m L104Q 
UbcH5m L104V 
Ubiquitin L8A 
Ubiquitin I44A 
Ubiquitin V70A 
Ubiquitin V70I 
 
Table 3.1. Mutations made in E4BU, UbcH5m, and Ubiquitin to characterize the 
function of the residues in ubiquitination activation. 
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binding, so these were the first tested to determine if UbcH5 binding was affected. 
Samples of the mutant proteins were prepared with 
15
N enrichment and NMR chemical 
shift perturbation experiments were performed. Upon titration of UbcH5 into either 
F1141A or R1143A E4BU20, the chemical shift perturbations of other residues in the 
binding interface are still observed. Hence, it was concluded that neither F1141A nor 
R1143A adversely affect UbcH5c binding (Figure 3.4).  
 
 
 To investigate the importance of the cross-over helix of UbcH5c on ubiquitin 
activation, Leu104 was selected for mutation because its side chain is exposed to solvent.  
Residues in the hydrophobic patch of ubiquitin previously shown to be critical for non-
covalent interactions (Leu8, Ile44, and Val70) were also selected for mutation. Finally, a 
mutation of Val70 to Ile was also made to analyze steric effects in the hydrophobic 
interface.     
Figure 3.4. Mutations along the E4BU:UbcH5 binding interface do not adversely affect 
E4BU:UbcH5 binding. A) 
15
N-
1
H HSQC of 
15
N-E4BU
F1141A
 in the absence (black) and 
presence (red) of UbcH5. B) Same as (A) but with 
15
N-E4BU
R1143A
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E4BU autoubiquitination assays were analyzed by coomassie stained SDS-PAGE 
as well as Western Blotting with anti-ubiquitin antibody. Strikingly, all 8 mutations are 
defective in autoubiquitination (Figure 3.5A, compare lane 6 to lanes 7-14). Wild-type 
UbcH5c functions normally with wtE4BU20 under these conditions, generating several 
autoubiquitination species. However, performing this assay with any of the eight mutants 
inhibits autoubiquitination activity, as clearly seen in the western blot analysis (Figure 
3.5A, bottom panel).   
In examining the results of these experiments, we recognized that E4BU20 
autoubiquitination does not produce high molecular weight polyubiquitination species. 
To determine if this observation is strictly a limitation of this particular small construct, 
we sought to produce a more complete U-box ligase since all efforts to produce full-
length E4B, or larger constructs were unsuccessful, we produced a Ufd2-E4BU chimera 
fusing the U-box domain of Mus musculus E4B to the substrate binding domain of 
Saccharomyces Cerevisiae Ufd2 (Ufd2
E4BU
). This chimera allowed us to test functional 
questions regarding the E4B U-box, but with the ease of production characteristic of 
Ufd2.  
 Autoubiquitination of Ufd2
E4BU 
produces the characteristic high molecular weight 
smear of highly polyubiquitined substrate (Figure 3.5B Lanes 6-8). Consequently, this 
chimera was used for probing the activity of the six Ub and UbcH5c mutants. These 
experiments showed some slight differences in autoubiquitination of Ufd2
E4BU
 versus 
E4BU. With regards to UbcH5c, L104Q completely abrogates ubiquitination activity, 
whereas L104V severely restricts, but does not completely inhibit ubiquitination (Figure 
3.5B, compare lanes 9 and 10). Similar observations are made with the ubiquitin mutants: 
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L8A and I44A completely disrupt ubiquitination activity whereas V70A and V70I appear 
to retain a small amount of activity (Figure 3.5B, lanes 11-14). Clearly, Leu104 and the 
three residues composing the hydrophobic patch of ubiquitin are essential for proper 
autoubiquitination of both E4BU and Ufd2
E4BU
.  
 
 
Figure 3.5. E4BU activates an allosteric network of residues in the ubiquitination 
machinery. A) Autoubiquitination of E4BU 1072-1173 was analyzed by SDS-PAGE. 
Negative controls (lanes 1-5), wild type reaction (lane 6), and mutant reactions (lanes 
7-14). Gels analyzed by both Coomassie stain (top panel) and Western Blotting with 
α-ubiquitin antibody (bottom panel). B) Autoubiquitination of Ufd2E4BU shows more 
high molecular weight ubiquitinated species. Controls (lanes 1-5), wild type reactions 
(lanes 6-8), and mutant reactions (lanes 9-14). Analyzed by Coomassie stain. C) 
Model surface representation of the E4BU:UbcH5~Ub complex with mutations of 
note represented in red. Generated by overlaying the HADDOCK model of 
E4BU:UbcH5 with the conjugate structure taken from NEDD4:UbcH5~Ub (PDB ID: 
3JWO).   
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Dynamics of Ubiquitin Activation 
 Although three-dimensional structures of UbcH5~Ub conjugates, UbcH5-Ub non-
covalent complexes, and UbcH5-E3 complexes are available, only minimal structural 
information has been reported for the ternary E3-E2~Ub complexes (28, 42, 53, 93). 
Schulman and colleagues determined the crystal structure of a HECT
NEDD4L
-UbcH5~Ub 
complex, and provided excellent insight into the transfer mechanism of Ub to the HECT 
E3 ligase (118). Despite offering glimpses into a ubiquitin transfer, this single structure 
provides only limited insight in ubiquitin activation. Moreover, the overwhelming 
majority of ubiquitin E3 ligases are of the RING or U-box family and do not directly 
interact with Ub as do HECT E3s. Consequently, many questions remain concerning how 
ubiquitin is activated for release from the E2 for U-box/RING E3 ligases. Here, we have 
applied an NMR approach to investigate the structure and dynamics of the E4BU-
UbcH5m~Ub complex.  
 To investigate the relative dynamics of the UbcH5m~Ub conjugate in the 
presence of E4BU, we measured residual dipolar couplings. For these experiments, 
15
N-
enriched ubiquitin was used to form the UbcH5m~Ub conjugate, and experiments were 
performed in the presence and absence of E4BU. Reduction in the degree of flexibility of 
ubiquitin in the conjugate should result in significant differences in the RDCs of the 
bound versus the unbound state using C12E5:hexanol as an alignment medium (121). 
Both proteins remained soluble upon addition of C12E5 and hexanol, and partial 
alignment was verified through deuterium splitting. Once these proper conditions for 
partial alignment were identified, a production run was performed. Surprisingly, no 
significant differences in RDCs of ubiquitin for the free conjugate versus the E4BU-
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Figure 3.6. Ubiquitin motion is not significantly altered by UbcH5~Ub:E4BU binding. 
A) Ubiquitin RDCs in the free state (red), conjugated to UbcH5 (green) and 
conjugated to UbcH5 in the presence of E4BU (grey). B) Comparison of Leu8 of 
ubiquitin from (L-R) free, conjugated to UbcH5c, and conjugated to UbcH5c bound to 
E4B. 
 
bound conjugate were observed (Figure 3.6). Since there are a number of optimization 
steps involved in obtaining reliable data, it is not yet clear if these observations are fully 
representative of the actual complex. At the very least, the samples need to be prepared 
again and the data re-measured. The fact that the conjugate is hydrolyzing over the course 
of the experiment poses the most severe problem and the extent of Ub release needs to be 
carefully monitored. Nevertheless, it is possible that there are no changes in the dynamics 
of Ub or perhaps that the changes fall outside the range of sensitivity of the method.  
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Discussion 
 Here we show that binding of the U-box domain of E4B catalyzes the hydrolysis 
of the covalent bond of the UbcH5c~Ub conjugate. NMR chemical shift perturbation 
experiments were used to investigate the underlying structural basis of this effect. These 
experiments reveal differences in binding of E4BU to the  UbcH5~Ub conjugate versus 
free UbcH5. The residues that appear to be affected in these interactions were identified 
and a few key mutations were made to test their role in the activation of UbcH5~Ub. 
These mutations severely restricted activity in in vitro autoubiquitination assays, 
suggesting the presence of an allosteric network within the E3-E2~Ub ternary complex. 
Preliminary residual dipolar coupling experiments were performed to examine the 
dynamics of ubiquitin in the ternary complex, but no significant differences were 
observed. The data presented here provides a framework with which to further investigate 
the mechanism of ubiquitin activation. 
Recent studies have begun to provide insights into the activation and transfer of 
ubiquitin from the E2~Ub conjugate to substrate. However, many questions remain. Here 
we provide evidence that binding to the E3 ligase triggers Ub activation via an allosteric 
mechanism. But how do these effects facilitate the hydrolysis of the UbcH5~Ub 
thiolester and subsequent transfer to substrate? Thorough characterization of the 
structural dynamics of the E3-E2~Ub complex will be required to understand the 
molecular basis for this key step in ubiquitination. 
Investigation of available structures of E2~Ub conjugates, as well as personal 
communication with the Klevit lab at the University of Washington, suggests a high 
degree of flexibility in the E2~Ub conjugate (42, 118, 120). Comparing structures of free 
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UbcH5~Ub conjugate (PDB ID: 3A33) with that of HECT
NEDD4L
-UbcH5~Ub (PDB ID: 
3JVZ), reveals remarkably different dispositions of ubiquitin with respect to the E2, 
spanning approximately 50-60 Å of conformational space (Figure 3.7). Therefore, we 
hypothesize that E2-E3 binding restricts the flexibility of ubiquitin, facilitating its release 
to the substrate targeted by the ligase. Evidence has been obtained that this restriction in 
flexibility favors a “closed” state conformation of the E3-E2~Ub complex. Apparently, 
these closed conformations are more readily hydrolyzed, thereby leading to accelerated 
release of Ub.  
 Additional dynamic measurements will be necessary to generate a full 
understanding of the effect of E3 on the E2~Ub conjugate. RDC measurements and/or 
NMR relaxation data have the potential to provide insights regarding the flexibility of 
ubiquitin in the presence and absence of the E3 ligase (122). RDCs can be used to 
characterize the dynamics of protein or protein complexes in addition to providing 
information on the folding of the protein or complex. NMR relaxation experiments 
measuring the backbone dynamics of a protein can be used to characterize its rotational 
diffusion. Together, complete sets of RDC measurements in conjunction with relaxation 
data should offer a detailed understanding of the relative structural dynamics of the 
E2~Ub conjugate, to enhance understanding of the mechanism for activation by the E3 
ligase. Characterization of the ubiquitin activation process will provide insight into 
ubiquitination substrate selectivity and the propagation of cellular signals. 
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Many hurdles exist in obtaining structural information for the E4BU-UbcH5c~Ub 
complex. The overall size of the complex is ~35 kDa and significantly moreso if a 
substrate is involved. The apparent flexibility in the E2~Ub conjugate and the transient 
nature of the bond between E2 and Ub, even if it is stabilized through an oxyester bond, 
will pose significant challenges because stability of many hours (at a minimum) is 
required for structural analysis. However, advances in solution methods such as Small 
Angle X-Ray Scattering (SAXS) offer a promising potential way forward (123, 124). 
Instead of pursuing static information of what is intrinsically a dynamic complex, SAXS 
and NMR have the potential to offer insight into movement and flexibility, and enable 
generation of dynamic models for this system. Moreover, these approaches could be used 
to build structurally dynamic models for multiple complexes - (1) isolated E2~Ub, (2) 
E2~Ub bound to E3, and (3) E2~Ub bound to E3 with substrate.  
Figure 3.7. Flexibility in the UbcH5c~Ub conjugate. The HADDOCK derived complex 
structure (Chapter II) of E4BU (beige) bound to UbcH5c (green) was used to demonstrate 
the flexibility of ubiquitin. Crystal structures of UbcH5~Ub conjugates (slate, 3A33 (42); 
blue, 3JWO (118)) were aligned with the E4BU-UbcH5c HADDOCK model using 
UbcH5c as the basis for alignment. Hydrophobic patch of ubiquitin is highlighted in 
yellow and Leu104 of UbcH5 is shown in red.    
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Function in diverse signaling pathways is made possible because ubiquitin is able 
to form a number of distinct chains. It is important to understand the molecular processes 
that govern how Ub modifies its substrates and the factors responsible for variability and 
substrate selectivity. Continued study into the dynamic mechanism of U-box/RING 
mediated ubiquitin activation and transfer will provide essential insight into ubiquitin 
specificity and has the potential to impact treatment of a number of ubiquitination-
associated diseases (5, 125). 
 
Methods 
Expression Plasmids.  
 Mouse E4B DNA was amplified with overhanging 5‟ BamH1 and 3‟ Xho1 
restriction sites for subcloning into in-house pBG vectors (L. Mizoue; Center for 
Structural Biology, Vanderbilt University). Residues 1092-1173 were subcloned into the 
pBG102 vector, which produces an N-terminal 6xHis-SUMO tag fusion protein. Human 
UbcH5c and UbcH5c (S22R/C85S) were produced as untagged constructs from pET28 as 
described previously (28). Human ubiquitin was produced with an N-terminal 6x-His tag 
from pET28a as described previously (119). 
 
Mutations 
 Mutations in E4B 1072-1173 were generated by site-directed mutagenesis. An 
initial stage of 2 cycles of amplification was used to generate requisite excess of product 
by amplifying the gene of interest with only forward or reverse primers in each reaction. 
Following this step, forward and reverse primer reactions are combined, and 
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amplification proceeds for an additional 15 cycles. Sample products were transformed 
directly into XL1-BLUE cells. Resulting colonies were picked and grown in LB
Kan
 
media, and plasmid DNA was isolated and purified (Qiagen). Mutations were confirmed 
through DNA sequencing by the Vanderbilt University DNA sequencing core.  
  
Protein Purification 
 Mus Musculus E4BU (1072-1173, 1072-1173
F1141A
, 1072-1173
R1143A
, and 1092-
1173), Homo Sapiens UbcH5c and UbcH5c (S22R/C85S) as well as Saccharomyces 
Cerevisiae Ufd2 (1-961) were overexpressed in the BL21(DE3) STAR strain of 
Escherichia coli. Ubiquitin was overexpressed in BL21(DE3) cell line. E4BU constructs 
were purified by Nickel affinity chromatography and the His-SUMO tag was cleaved by 
H3C precision protease. A second purification step with the same column removed the 
affinity tag from the sample. The proteins were further purified by anion-exchange 
chromatography using a SourceQ column and Superose6 gel filtration chromatography. 
UbcH5c constructs were purified by cation exchange chromatography using SP resin, 
followed by size-exclusion chromatography with an S75 column.  Ufd2 and ubiquitin 
were purified by Nickel chromatography followed by size exclusion chromatography 
with an S75 column. Protein concentrations were determined by using a calculated 
extinction coefficient for each protein. The E4BU, UbcH5, and Ufd2 extinction 
coefficients were calculated at 280 nm, whereas the value for ubiquitin was calculated at 
277 nm. Protein samples for NMR experiments were expressed in minimal media with 
NH4Cl and glucose as the sole nitrogen and carbon sources, respectively. 
15
NH4Cl and 
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[
13
C6]glucose (Cambridge Isotope Laboratories) were used as needed to prepare the 
requisite isotopically enriched proteins.  
 
UbcH5~Ub conjugation 
 Purified UbcH5 (S22R/C85S) in 25 mM Na2HPO4 and 150 mM NaCl at pH 7.0 
was incubated with purified ubiquitin in the same buffer in a 1:2 molar ratio, respectively. 
5 µM Uba1, 5 mM ATP, and 10 mM MgCl2 were added, and the reaction mixture was 
incubated for 4-5 hours at 30 °C. Reaction components were separated by an additional 
step of size exclusion chromatography using an S75 column equilibrated in reaction 
buffer or Sodium Acetate at pH 5.0 with 150 mM NaCl. Conjugated UbcH5~Ub samples 
were used immediately after purification.  
 
NMR chemical shift perturbations 
 NMR experiments were conducted using a Bruker DRX 600 MHz spectrometer 
equipped with a z-axis gradient TXI cryoprobe. The NMR chemical shift perturbation 
assays employed either 
15
N-E4BU and unlabeled UbcH5c or 
15
N-UbcH5c and unlabeled 
E4BU. The NMR samples contained 100 µM 
15
N-protein in 25 mM NaH2PO4 at pH 7.0, 
150 mM NaCl, and 5% D2O. Unlabeled protein in the same buffer was added to the 
labeled sample until the molar ratio reached 1:2 (
15
N labeled:unlabeled). 
 
Residual Dipolar Couplings 
 All proteins were aligned in 5% pentaethylene glycol monododecyl ether (C12E5) 
brought into nematic phase with addition of hexanol. 500 μl 15N-enriched protein in 25 
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mM Na2HPO4 at pH 7.0 (or 25 mM NaC2H3O2 at pH 5.0), 150 mM NaCl, and 10% D2O 
was added to 25 μl C12E5 and vortexed thoroughly. Hexanol was added in 1 μl 
increments until solution turns from milky and turbid to translucent. Alignment of 
samples was checked by deuterium splitting where acceptable values range from 23-26 
Hz (126). All IPAP 
15
N-
1
H HSQC experiments were collected on a Bruker DRX 600 
spectrometer equipped with a TCI cryoprobe (127).   
 
In vitro autoubiquitination assays 
Ubiquitination experiments were carried out at a final volume of 20 µl with E1 
(BostonBiochem) at 52 nM, UbcH5c at 0.6 µM, ubiquitin (BostonBiochem) at 50 µM, 
and either E4B 1072-1173 or Ufd2 at 1 µM. The assay was performed in buffer 
containing 100 mM NaCl, 1 mM DTT, 5 mM MgCl2 and 25 mM Tris-Cl at pH 7.5. The 
reactions were activated with 5 mM ATP and incubated at 30 
o
C for 60 minutes. To 
quench the ubiquitination reaction, the samples were incubated for 15 minutes at 90 
o
C. 
Gels were run on 4-12% Bis-Tris gradient polyacrylamide (Invitrogen) and detected by a 
SimplyBlue SafeStain (Invitrogen). Western blot analysis was completed using an 
enhanced chemiluminescence reagent (Thermo Scientific). Polyclonal α-ubiquitin 
primary antibody at a 1:1000 ratio and secondary α-mouse antibody at a 1:7000 ratio 
were used for detection. A 60 second exposure time was used for film development.  
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CHAPTER IV 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Summary of this work 
Structure of the E4B U-box domain 
 The structure of the U-box domain from Mus musculus E4B was determined via 
NMR spectrometry. As anticipated, it is structurally homologous to the U-box domain of 
the yeast homologue, Ufd2, previously determined by X-ray crystallography, and aligns 
with an rmsd of 1.15 Å over all backbone atoms. Analogous to other U-box and RING 
structures, E4BU contains an elongated α-helix at its C-terminus. In previously studied 
U-box and RING-containing ligases, this C-terminal helix acts as part of a dimerization 
motif, either creating homodimers such as the case for the U-box containing proteins 
Prp19 and CHIP, or heterodimers in the case of RING protein complexes 
BRCA1/BARD1, Mdm2/MdmX, and Ring1/Bmi1 (53-57).  
Unlike all other U-box and RING domain E3 ligases, E4B was found to be 
monomeric in solution. Although initial qualitative analysis by size-exclusion 
chromatography suggested E4BU was a dimer, quantitative analysis by SEC-MALS, 
AUC, and ESI-MS all confirmed the predominance of a monomeric state in an 
approximate 10:1 ratio versus dimer. We went to great lengths to be sure of this because 
all other structurally characterized U-box domains are dimers and it has been shown that 
inhibition of dimerization compromises ubiquitination function (53, 54, 95). In the case 
of CHIP, oligomerization has been proposed to provide flexibility to the ligase, 
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increasing processivity of ubiquitination while enabling accommodation of substrates of 
various sizes (63). Clearly, additional research is needed to understand why E4B exists as 
a monomeric E3 ligase.  
The structural information obtained about the E4B U-box domain has been related 
to E2 interactions. NMR chemical shift perturbation analysis was used to map the binding 
interface of E4BU and UbcH5c, and this residue specific data was used to generate a 
computation model of the UbcH5c-E4BU complex. The model reveals a distinct binding 
interface centered on the central α-helix of E4BU in addition to the two flanking loop 
regions. These three structural elements interact with helix 1, and loops 4 and 7 of 
UbcH5c. This binding interface is very similar to that observed for other U-box-E2 
complexes (53, 93). Based on our analysis to date, E4B appears to be unique in that it 
only interacts with UbcH5 E2 enzymes. Additional study to fully characterize the E2 
selectivity of E4B would be of great interest with respect to gaining better understanding 
of ubiquitination specificity resulting from pairing of E2 conjugating and E3 ligating 
enzymes.  
 
Function of E4B  
Despite its unique monomeric state, E4BU functions in in vitro autoubiquitination 
assays. E4BU binds and ubiquitinates using the UbcH5 family of E2 conjugating 
enzymes, and is readily capable of catalyzing poly-ubiquitin chain synthesis without the 
need for any additional E2 (or E3) enzymes (Figure 2.9 and 3.5). Surprisingly, our 
preliminary E2 screening showed that E4BU functions only with the UbcH5 family 
(Figure 4.1-2). This observation coincides with UbcH5 enzymes being used in all 
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Figure 4.1. Ufd2-E2 screening. Ufd2 was subject to in vitro 
autoubiquitination assays using a subset of different E2 enzymes.  
published studies of E4B and Ufd2 function (66, 68, 72, 101). However, it should be 
noted that a systematic and complete survey of all E2 conjugating enzymes has yet to be 
performed. This would require additional experiments exploring for example 
optimization of conditions for the assay, and examination of ubiquitination activity on 
substrates.  
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Figure 4.2. E4B was tested for function with a variety of E2 enzymes in in vitro 
autoubiquitination assays. A) Enzymes UbcH5a, UbcH5c, Ube2e1, Ube2e2, and 
Ubc13/Uev1. Detection via Coommassie stain (left) and α-Ub antibody (right). B) 
Enzymes UbcH2, Ube2r1, Ube2e1, Ube2l3, Ube2e2, Ube2c1, and Ubc13/Uev1. 
Coomassie stain (left) and  α-Ub antibody (right). Figure courtesy of Yoana Dimitrova. 
 
84 
 
The UbcH5 E2 enzymes are best known for their promiscuity. Nevertheless, 
function with only these E2s would be intriguing (46). In particular, one may be led to 
ask what cellular role E4B has if it only requires broad, unspecific ubiquitination of 
substrates as generally observed with UbcH5. E4B/Ufd2 has primarily been implicated in 
ubiquitin-mediated proteasomal degradation of substrates such as UNC-45, ataxin-3, and 
Ste6p* (68, 101, 128). In addition to these roles in proteasome-dependent degradation, 
Ufd2 has also been shown to polyubiquitinate FEZ1, a regulator of neuritogenesis, via 
Ub
K27
 linkages that do not promote degradation, but rather function in an as of yet 
unidentified pathway (72). E4B has also been shown to polyubiquitinate securin, a factor 
in sister chromatid exchange separation, but it remains to be seen whether or not this 
results in degradation via the proteasome (129). Clearly, E4B ubiquitinates many 
different substrates, but further study is necessary to generate a more general 
understanding of its role in cellular function. 
A critical role for the E3 ligase in ubiquitin activation and transfer to substrates 
has been previously demonstrated for RING type E3 ligases (130). The work in this 
thesis suggests a similar role for the U-box domain of E4B. A few key residues in 
ubiquitin, UbcH5c, and E4BU were identified and shown to be essential for triggering 
activation of the UbcH5c~Ub conjugate, suggesting the existence of an allosteric 
mechanism for this process. To further characterize the role of E4B in the cell, it will be 
necessary to identify any additional E2 enzymes with which it interacts and functions. It 
will then be imperative to expand upon these findings and investigate potential allosteric 
networks for other E2-E4B pairs and determine whether or not these networks are 
conserved from E2 to E2. Interestingly, reports from the Klevit laboratory indicate that a 
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similar allosteric network exists for the RING E3 heterodimer BRCA1/BARD1. In 
particular, they found that L63A and K65A mutations in BRCA1 abrogate ubiquitin 
transfer, just as mutations in the analogous E4BU residues F1141A and R1143A. The 
mutations in UbcH5c and ubiquitin used in our study also inhibited ubiquitination 
activity, as we observed for E4BU. Together, the data on E4BU and BRCA1/BARD1 
suggests that this allosteric network may be a common mechanism used to promote the 
activation of the E2~Ub conjugate. Moreover, these results suggest E4BU is an excellent 
model system for future study of ubiquitin activation and transfer. E4B is highly 
attractive as a model system because as a monomer it has clear advantages over the 
RING and U-box protein dimers for structural analysis.   
   
Future Directions 
Production of full-length mammalian E4B 
Full-length protein is required n order to fully understand the function of E4B. 
Attempts to express full-length E4B in E.coli cells were unsuccessful, most likely due to 
the sheer size of this protein, since bacteria do not typically produce such large proteins. 
While sequence analysis suggests conservation of the coiled-coil motifs, and the 
structural studies contained in Chapter II validate the homology of the U-box domain, the 
structure of the core amino acids of E4B is not known. During the course of this thesis 
work, various constructs of the N-terminal domain of E4B were designed and tested for 
expression and solubility, but all proved to be prone to rapid degradation or insoluble. 
Shifting recombinant expression of these constructs, as well as the full-length protein, to 
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either insect or mammalian cells is the next logical step toward achieving the goal of 
producing full-length E4B and large N-terminal fragments.  
 One of the pressing questions about mammalian E4B is whether or not it 
functions in proteasome shuttling like its yeast counterpart, Ufd2. Because other aspects 
of Ufd2 function have been validated in E4B (such as p97 and CHIP interactions), it is 
anticipated that interactions with Rad23 and Dsk2 homologues would also be preserved. 
If E4B does not share these properties, it would most likely mean that additional factors 
play a part in mammalian proteasome shuttling, and in order to effectively characterize 
the proteasome response, these factors would need to be identified.    
  
E4B function with E2 enzymes 
 The UbcH5 family (Ubc4 in lower eukaryotes) are the only E2 conjugating 
enzymes currently known to function with E4B. Functioning exclusively with the H5 
family would be intriguing since most other E3 ligases appear to be able to interact with 
multiple E2 conjugating enzymes, a factor that is key in generating the diversity of 
polyubiquitin chain types (12, 53). Furthermore, research shows that multiple E2 
enzymes, and even multiple E2-E3 pairs are necessary to catalyze polyubiquitin chain 
synthesis (11-13, 39). While UbcH5 enzymes alone are effective in synthesizing chain 
elongation, it is important to identify if any other E2 enzymes function with E4B as part 
of the effort to understand E4B function. My initial screens of E4BU and Ufd2 with 
seven additional E2 enzymes did not reveal autoubiquitination activity function for any of 
these, but it will be necessary to perform this search more systematically as described 
above. A yeast two-hybrid approach has previously been employed to explore E2-E3 
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interactions for BRCA1/BARD1 and this could be quite valuable as well for E4BU (12). 
Once E2 conjugating enzymes that interact are identified, binding to E4BU can be 
characterized in more detail by NMR chemical shift perturbation analysis and function 
assessed by in vitro autoubiquitination assays, as demonstrated in Chapter II of this 
thesis.   
 
E4B substrate identification 
 Neither the substrate binding domain, nor the substrates of E4B are known. 
Production of full-length E4B, or a ΔU-box fragment is necessary to identify its 
substrates. Yeast two-hybrid or protein microarray screening provide potential avenues to 
E4B binding partners, and thus possible substrates. This information is not only essential 
to fully understand the purpose of E4B in the cell, but would also provide the substrate 
required to further elucidate the detailed mechanism of ubiquitin transfer. Current 
ubiquitination activity assays rely on autoubiquitination of E4B. Testing ubiquitination 
assays on a substrate may reveal E2-E4B interactions and functional nuances that are not 
evident from study of autoubiquitination alone. Consequently, comparison to substrate 
ubiquitination is absolutely essential.  
 The central armadillo-like repeat domain of Ufd2 has a high degree of sequence 
similarity with the analogous region of E4B. The crystal structure of Ufd2 shows an 
elongated structure, spanning approximately 146 Å in total length (43). Because of this 
large distance, it is believed that the substrate binding region of Ufd2/E4B is located 
proximal to the C-terminal U-box. If this were not the case, ubiquitin transfer from the U-
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box bound conjugate would potentially become inefficient since there would be a large 
gap in atomic space between the bound substrate and U-box bound E2~Ub conjugate.    
 
Understanding ubiquitination dynamics 
 Many questions still remain concerning the molecular basis for ubiquitin transfer 
to a substrate. While we have established the presence of an allosteric network, structural 
understanding of the mechanism at the atomic level is lacking. The two main hurdles in 
characterizing the structural basis of ubiquitin activation and transfer are (1) utilizing 
biophysical techniques that characterize the dynamics of the complex, and (2) developing 
the requisite methods for these large molecular weight complexes. For example, the 
studies carried out in Chapter III were initially proposed for the study of the RING E3 
BRCA1/BARD1 heterodimer. However, the high molecular weight of the dimeric 
complex severely limits the quality of the NMR data. Similar problems have also been 
encountered for NMR studies of the CHIP U-box homodimer (S.E. Soss, personal 
communication). The unique monomeric nature of E4BU makes it an excellent structural 
model for such studies.  
 X-ray crystallography is the most common technique employed to study multi-
protein complexes since it is not limited by high molecular weights like NMR. However, 
the downside to this method is the static nature of the structural information, which can 
be limiting if dynamics are critical to the mechanism of action. Since ubiquitin transfer is 
a dynamic process, more than a crystallographic snapshot is required. NMR is uniquely 
well suited to address this problem. In particular, the application of new NMR techniques 
such as TROSY, CRINEPT, and CRIPT on deuterated proteins allow for study of higher 
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molecular weight systems (131). However, because these techniques are relatively new 
and require substantial optimization, it is not yet clear if they provide a universal solution 
for studying the mechanism of activation of the E2~Ub conjugate and Ub transfer. Using 
E4BU as a model substrate has allowed us to construct an E3-E2~Ub model without the 
need for specialized techniques, and the potential for using full-length E4B for further 
analysis appears promising.  
 Preliminary residual dipolar coupling data were acquired for E4BU-UbcH5c~Ub 
complex. These results, while inconclusive, suggest the method can be used to obtain 
information about the dynamics of ubiquitin and how they change when E4BU binds to 
the UbcH5c~Ub conjugate. The data presented in Chapter III shows RDCs measured 
from one type of alignment media, but it is likely that different alignment media will be 
needed to complete the analysis since evidence for interaction between UbcH5c and the 
alignment media was obtained. NMR relaxation data offers an alternative approach to 
obtain information about the dynamics of the system. We firmly believe that the dynamic 
flexibility of Ub in the conjugate is shifted when the conjugate is bound to E4B, and that 
this effect catalyzes Ub transfer to the substrate.  
  SAXS may also prove useful for generating a working molecular model of the 
dynamic process of ubiquitin transfer. Despite the low resolution of the structural data 
obtained, SAXS is not limited by molecular weight and it has potential to provide insight 
into dynamic systems (123). The approach would involve building up a series of 
experiments on the isolated proteins, sub-complex, and the full ubiquitination machinery. 
Initial assessment of the E2~Ub conjugate alone should reflect a molecular envelope with 
a high occupancy of molecular space. Upon addition of the U-box domain (and 
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eventually full-length E4B), the change in ubiquitin dynamics should be directly 
observed in a reduction in the conformational envelope. Once E4B substrates are 
identified, inclusion into the SAXS studies will provide crucial insight relating how 
ubiquitin is positioned for transfer to substrates. Such a dynamic structural model will 
offer unprecedented insight into the mechanism for protein ubiquitination. 
 
Implications of this work 
 The proteome may encode more enzymes (activating, conjugating, ligating, and 
deubiquitinating) associated with the ubiquitination pathway than any other signaling 
pathway in the cell (132). Understanding how these enzymes interact to elicit distinct and 
specific responses is of critical importance for understanding the various disease 
processes associated with faulty ubiquitination. Miscommunication or defects in the 
ubiquitination process can result in developmental defects as well as a vast array of 
diseases such as cancer and neurodegenerative diseases (reviewed in (5)). By identifying 
the defects in ubiquitination, it is hoped that new therapeutic strategies for treatment of 
disease could be developed. For example, if it is found that ubiquitin is not being 
transferred to the substrate correctly, the ubiquitin activation process can be investigated 
and potentially targeted by small molecules to increase or decrease substrate affinity. In 
addition to analyzing the mechanism of ubiquitination, insights into proteasome function 
also offer multiple avenues for therapeutic development (133).  
Currently, the ubiquitination pathway is a hotbed of activity for disease 
identification and treatment. Proteasome targeting is of high interest in drug 
development. Proteasome inhibitors are now being developed as potential cancer 
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chemotherapeutics (134-136). However, global proteasome inhibition creates its own set 
of problems because it may not be able to effectively differentiate between those 
substrates that require degradation and those that should not be degraded. Because E4B is 
hypothesized to factor in proteasome shuttling, it could be a likely target for therapeutics 
upstream of the proteasome itself. This potential can be assessed once a more complete 
set of E4B substrates is identified. 
Structural study of ubiquitination associated proteins and their complexes is 
leading to a detailed understanding of the ubiquitination cascade at the atomic level. This 
atomic level information provides a solid foundation for identification of potential drug 
targets. E3 ligases such as E4B are a prime target. For example, since the ligase appears 
to be responsible for recruiting specific substrates, targeting of these interactions has the 
potential for selective inhibition of a ubiquitination process. In instances of unregulated 
ubiquitination leading to unwanted substrate degradation, such as that seen for CFTR, 
this strategy offers a logical therapeutic direction (137). E4B and the proteins with which 
it interacts should be readily amenable to this approach, once the explicit functional roles 
and any associated pathologies are unambiguously identified. 
  
E4B and the ERAD pathway 
 The most studied functional role for E4B, as well as its Saccharomyces cerevisiae 
and Caenorhabditis elegans homologue Ufd2, is in the ERAD pathway. During nascent 
polypeptide secretion to the cytosol via the ER, checkpoints are employed to verify 
proper folding in order to preserve native cellular function. In the event of a misfolded 
protein, the homohexameric AAA+ ATPase p97 (Cdc48 in yeast) extracts the misfolded 
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substrate and begins the process of signaling for degradation. It has been proposed that 
E4B binds to p97 and functions as a chaperone in response to misfolded proteins (77). 
Despite the conservation between Cdc48 and p97, and between Ufd2 and E4B, the 
interactions of these proteins differ.  In the lower eukaryotes, Ufd2 interacts with the C-
terminal tail region of Cdc48 (138). In constrast, in the mammalian system, E4B interacts 
with the N-terminal domain of p97 (139). It is not yet known why these two homologs 
differ. 
 Ufd2 is also known to associate with the proteasome shuttling factors, Rad23 and 
Dsk2, but these interactions have yet to be characterized for E4B in higher order 
eukaryotes (138, 140).  Rad23 and Dsk2 are UBA-UBL proteins, containing carboxy 
terminal ubiquitin binding domains and an amino terminal ubiquitin-like domain. It has 
been proposed that Ufd2 will function as a scaffolding protein, bridging Cdc48 and the 
UBL domain of Rad23/Dsk2 (140). Therefore, a misfolded substrate identified by Cdc48 
could then be passed onto Rad23/Dsk2, and trafficked to the proteasome for removal. 
This is a likely scenario, since the binding sites of Cdc48 and Rad23 do not overlap on 
Ufd2. However, further study is warranted to establish if this is a valid model. It should 
be noted that there are significant differences between E4B and Ufd2. For example, the 
N-terminus of Ufd2 is not conserved in E4B. This difference may explain why Ufd2 
interacts with Rad23, but no interaction has been identified between E4B and hHR23.  
 When initially characterized, Ufd2 was classified as an “E4” enzyme (66).  It was 
observed that an engineered substrate was polyubiquitinated only in the presence of both 
the HECT E3 ligase Ufd4 and Ufd2. Separately, Ufd2 and Ufd4 could only catalyze 
monoubiquitination on the substrate, which is not sufficient for recognition by the 
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proteasome. This observation has implications in the context of the ERAD pathway as 
well. In the absence of Ufd2, a substrate may only be mono- or di-ubiquitinated. Once 
Ufd2 is recruited by Cdc48, sufficient chain elongation may take place to target the 
substrate for degradation by the proteasome. This extra step in the pathway may serve as 
another checkpoint before the substrate is removed from the ER.   
 
E4B and interaction with CHIP 
Another study reported a similar phenomenon of E4 activity: the C. Elegans 
protein UNC-45 was only minimally ubiquitinated in the presence of either Ufd2 or 
another U-box E3 ligase, CHN-1 (homologue of CHIP). Ufd2 was found to interact with 
CHN-1, and this interaction was necessary to generate sufficient polyubiquitin chains on 
the substrate (68). There is evidence that E4B interacts with CHIP as well, but 
identification of the respective binding regions and structural characterization of this 
complex has yet to be reported (69). It is intriguing to consider what might be the overall 
oligomerization state of this assembly. For example, does CHIP still adopt a dimeric 
architecture when bound to E4B/Ufd2? Is CHIP dimerization somehow disrupted by the 
presence of E4B/Ufd2? Studies of CHIP reveal that its unique asymmetric dimeric form 
increases the processivity of the ligase (63). Perhaps a similar effect would be observed 
in the context of an E4B/CHIP complex. 
I attempted to narrow down the binding region on E4B of the CHIP interaction 
using pull-down assays. Preliminary data suggests that E4B does, in fact, bind CHIP. The 
C-terminal half of E4B, spanning residues 742-1173 was found to effectively pull-down 
full-length CHIP from CNBr activated resin (Figure 4.3). Further studies are necessary to 
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Figure 4.3. The C-terminal half of E4B binds to CHIP. Full-length CHIP (1-303) was 
recombinantly purified and bound to CNBr-activated resin. Input E4B (742-1173) was 
added to the beads in molar excess. The beads were thoroughly washed and sample 
retention was analyzed by boiling a sample of the beads and analyzing via SDS-
PAGE. Figure courtesy of Dario Gutierrez. 
confirm this observation and narrow down the binding region on E4B, and ultimately 
identify the residues on CHIP that mediate this interaction. NMR chemical shift 
perturbation analysis may prove to be a useful tool for this analysis, as it can specifically 
identify the residues on the protein in the binding interface. This data could then be used 
to design appropriate constructs for crystallographic-based structural studies of the 
complex. Characterizing a unique heteromeric E4B/CHIP E3 ligase would provide new 
insight into the molecular basis for the putative E4 ligase activity, and possibly more 
generally impact understanding of polyubiquitin chain elongation.  
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Significance 
 Structural and functional characterization of the U-box domain of the E3 ubiquitin 
ligase E4B provides an excellent system for elucidation of the mechanism of ubiquitin 
activation. While much information is now known both structurally and functionally 
about the ubiquitination process, critical gaps in knowledge still remain concerning how 
ubiquitin is activated in an E2 conjugate and how it is then transferred to a substrate. 
Because ubiquitin is able to elicit different cellular signals through the location or type of 
polyubiquitin chain on a substrate, elucidating the mechanism of ubiquitination activation 
and transfer is of utmost importance to fully understand the complete function of 
ubiquitination and how defects in this pathway relate to disease.  
 The E4B U-box domain structural studies presented in this thesis suggest that like 
Ufd2, E4B is a monomeric protein, unlike other members of the U-box family. A 
monomeric protein is highly advantageous for structural analysis. Based on the 
similarities of E4BU-UbcH5 binding compared with other RING and U-box E3 ligases, it 
is implicated that mechanistic insights of ubiquitin activation generated from E4BU 
studies will apply to other E3 ligase systems as well. 
 Once further understanding of ubiquitin activation and transfer is obtained, 
investigation of defects within this pathway can be made. Many diseases are thought to 
result from problems of the ubiquitin system, but precise knowledge of where these 
problems exist along the pathway remains to be determined. If it is known that ubiquitin 
is not being transferred to a substrate correctly, or if association between the E3 ligase 
and substrate is negatively affected, then proper therapeutic measures can be pursued. 
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The work completed here using the U-box domain of the E4B ubiquitin ligase offers 
exciting new insight into the ubiquitin activation process.   
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APPENDIX A 
Table A.1. E4BU backbone chemical shifts 
Residue Atomic Chemical Shift 
  CA CB H N 
P1089 63.53 32.12 - - 
G1090 45.33 - 8.647 110.3 
S1091 58.45 63.97 8.136 115.6 
A1092 52.61 19.34 8.38 125.7 
E1093 56.41 30.25 8.245 120 
I1094 60.64 38.7 7.988 122.7 
D1095 53.42 41.74 8.23 125.1 
Y1096 57.3 38.15 8.546 122.9 
S1097 61.61 63.13 8.683 117.3 
D1098 52.98 39.26 8.814 119.6 
A1099 50.88 17.83 7.655 123.4 
P1100 62.34 31.83 - - 
D1101 58.07 40.44 8.364 122.4 
E1102 58.19 28.49 9.237 116.4 
F1103 53.47 37.53 7.622 115 
R1104 54.96 32.33 7.546 118.8 
D1105 53.41 46.98 9.312 125.9 
P1106 64.59 31.58 - - 
L1107 56.57 44.06 9.281 122.7 
M1108 54.05 33.37 9.622 116.3 
D1109 56.14 40.89 8.609 118.7 
T1110 59.01 70.32 6.921 105.5 
L1111 56.06 42.39 8.411 122.9 
M1112 57.04 35.41 8.791 127.7 
T1113 62.45 70.24 8.022 108.6 
D1114 51.78 41.22 8.677 121.3 
P1115 62.99 33.19 - - 
V1116 58.53 35.83 9.68 117.4 
R1117 54.84 32.85 9.794 122.9 
L1118 54.95 40.06 8.939 130.5 
P1119 65.94 31.6 - - 
S1120 59.05 63.53 8.058 109.7 
G1121 44.71 - 8.601 111.8 
T1122 63.96 69.62 7.353 119.1 
V1123 61.16 32.79 8.26 128.3 
M1124 54.87 38.52 9.041 123.3 
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Table A.1. Continued 
D1125 55.18 43.87 10.02 120.6 
R1126 60.73 30.42 8.979 128.6 
S1127 61.7 62.33 8.853 110.5 
I1128 64.02 37.15 7.026 122.4 
I1129 60.19 37 8.06 119.3 
L1130 58.66 40.51 8.58 123.3 
R1131 59.5 29.71 7.284 118.1 
H1132 60.64 30.63 7.683 120.2 
L1133 56.33 42.05 8.465 118.4 
L1134 57.36 42.16 7.247 117.9 
N1135 53.95 40.7 7.374 113.8 
S1136 54.7 64 7.798 114.6 
P1137 62.36 27.93 - - 
T1138 58.88 73.6 8.579 111.9 
D1139 51.35 43.04 8.686 122.6 
P1140 63.79 30.9 - - 
F1141 59.14 38.81 9.165 117.1 
N1142 52.16 39.14 8.441 116.6 
R1143 58.28 27.3 8.09 113.3 
Q1144 55.79 29.53 8.204 118.7 
M1145 57.55 32.2 8.395 121.1 
L1146 54.33 46.26 7.833 127.4 
T1147 58.95 71.82 7.349 112.5 
E1148 59.53 29.19 9.179 121.3 
S1149 60.29 62.75 8.148 113.2 
M1150 56.77 33.92 7.607 118.8 
L1151 54.72 41.89 7.22 117.2 
E1152 52.81 32.42 8.125 123.4 
P1153 63.71 33.04 - - 
V1154 59.16 30.81 7.446 119.1 
P1155 65.41 31.69 - - 
E1156 59.76 28.19 9.729 119 
L1157 56.69 42.28 6.791 120.7 
K1158 60.88 32.66 7.734 120 
E1159 59.36 29.26 8.055 116.3 
Q1160 59.36 28.99 7.535 120.3 
I1161 66.03 38.02 8.258 122.3 
Q1162 59.53 28.07 8.264 118.1 
A1163 55.44 18.06 8.259 122.1 
W1164 62.2 29.17 8.122 122 
M1165 59.75 33.54 8.871 117.8 
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R1166 59.53 30.13 8.011 118.6 
E1167 58.79 29.14 7.732 120 
K1168 56.91 31.42 7.614 118.9 
Q1169 56.67 29.04 7.687 116.8 
S1170 58.9 64.06 7.798 114.7 
S1171 58.6 64.02 8.058 117.1 
D1172 54.54 41.06 8.257 122.3 
H1173 57.02 29.92 7.814 122.7 
 
 
 
 
 
 
 
 
 
 
 
Table A.1. Continued 
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Figure B.1. Assigned 
15
N-
1
H HSQC spectrum of E4B residues 1092-1173.  
APPENDIX B 
Additional Figures 
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Figure B.2. 
15
N-enriched E4BU titrated with UbcH5 at molar equivalents of 1:0.13 
(orange), 1:0.25 (yellow), 1:0.5 (green), 1:1 (violet), and 1:2 (blue). Baseline spectrum 
shown in red.  
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Figure B.3. 
15
N-enriched UbcH5 titrated with E4BU at molar equivalents of 1:0.13 
(orange), 1:0.25 (yellow), 1:0.5 (green), 1:1 (violet), and 1:2 (blue). Baseline spectrum 
shown in red.  
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Figure B.4. Ufd2 was tested for E4 ubiquitination activity in the presence of CHIP 
against a variety of E2 enzymes. Ufd2 and CHIP were incubated together during an 
in vitro autoubiquitination assay with various E2 conjugating enzymes and the level 
of autoubiquitination on Ufd2 and CHIP was detected by Coommassie stain.  
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